<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0065">
    <title>48 Bordetella and Related Genera</title>
    <sect1 id="ch0065s0001">
      <title>48 Bordetella and Related Genera</title>
      <anchor id="ch0065s000001a0001"/>
      <anchor id="ch0065s000000a0001"/>
      <para role="chapterAuthor"><phrase role="center">PAUL E. KILGORE AND TOM COENYE</phrase>
      </para>
      <sect2 id="ch0065s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0065s000001a0002"/>
        <anchor id="ch0065s000000a0002"/>
        <para id="ch0065s000000p0001">The genera<emphasis>Bordetella, Achromobacter, Alcaligenes, Kerstersia, Advenella</emphasis>, and <emphasis>Paenalcaligenes</emphasis> belong to the family <emphasis>Alcaligenaceae</emphasis> (order <emphasis>Burkholderiales</emphasis> in the <emphasis>Betaproteobacteria</emphasis>) (<link linkend="ch0065s000000li0001">1</link>).</para>
        <para id="ch0065s000000p0002">The genus<emphasis>Bordetella</emphasis> contains 15 species: <emphasis>Bordetella avium, B. bronchialis, B. bronchiseptica, B. flabilis, B. hinzii, B. holmesii, B. muralis, B. parapertussis, B. pertussis</emphasis> (the type species), <emphasis>B. petrii, B. pseudohinzii, B. sputigena, B. trematum, B. tumbae</emphasis>, and <emphasis>B. tumulicola</emphasis> (<link linkend="ch0065s000000li0002">2</link>–<link linkend="ch0065s000000li0006">6</link>). Other putative species, such as “<emphasis>B. ansorpii</emphasis>,” and other strains similar to <emphasis>B. trematum</emphasis> have been described but not validly named. <emphasis>B. pertussis, B. parapertussis</emphasis>, and <emphasis>B. bronchiseptica</emphasis> could be considered a single species, but chemotaxonomic differences and differences in host range and pathogenesis (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0007">7</link>) support their status as separate species. Analysis of their genome sequences reveals that <emphasis>B. parapertussis</emphasis> and <emphasis>B. pertussis</emphasis> are independent derivatives of a <emphasis>B. bronchiseptica</emphasis>-like ancestor (<link linkend="ch0065s000000li0007">7</link>). The taxonomy of the genus <emphasis>Achromobacter</emphasis> is closely intertwined with the genus <emphasis>Alcaligenes.</emphasis> The genus <emphasis>Alcaligenes</emphasis> is now limited to <emphasis>Alcaligenes aquatilis, A. faecalis</emphasis> (the type species), <emphasis>A. pakistanensis, and A. endophyticus</emphasis>, while the genus <emphasis>Achromobacter</emphasis> consists of 20 species: <emphasis>Achromobacter aegrifaciens, A. agilis, A. aloeverae, A. animicus, A. anxifer, A. deleyi, A. denitrificans, A. dolens, A. insolitus, A. insuavis, A. kerstersii, A. marplatensis, A. mucicolens, A. pestifer, A. piechaudii, A. pulmonis, A. ruhlandii, A. spanius, A. veterisilvae</emphasis>, and <emphasis>A. xylosoxidans</emphasis> (the type species) (<link linkend="ch0065s000000li0003">3</link>, <link linkend="ch0065s000000li0006">6</link>, <link linkend="ch0065s000000li0008">8</link>–<link linkend="ch0065s000000li0014">14</link>). In addition, this genus contains several yet-unnamed genogroups (<link linkend="ch0065s000000li0015">15</link>). The genus <emphasis>Kerstersia</emphasis> was proposed for a set of strains phenotypically resembling <emphasis>A. faecalis</emphasis>; this genus contains two species (<emphasis>Kerstersia gyiorum</emphasis> and <emphasis>K. similis</emphasis>) (<link linkend="ch0065s000000li0008">8</link>). Similarly, the genus <emphasis>Advenella</emphasis> was created to harbor a number of <emphasis>Alcaligenes</emphasis>-like strains; these strains belong to <emphasis>Advenella alkanexedens, A. faeciporci, A. incenata</emphasis>, or one of several unnamed genomic species (<link linkend="ch0065s000000li0016">16</link>, <link linkend="ch0065s000000li0017">17</link>) or were previously described as <emphasis>Tetrathiobacter</emphasis> species (<link linkend="ch0065s000000li0017">17</link>). Finally, the genus <emphasis>Paenalcaligenes</emphasis> contains three species (<emphasis>Paenalcaligenes hermetiae, P. hominis</emphasis>, and <emphasis>P. suwonen</emphasis><emphasis>sis</emphasis>) (<link linkend="ch0065s000000li0018">18</link>).</para>
      </sect2>
      <sect2 id="ch0065s0001s0002">
        <title>DESCRIPTION OF THE GENERA</title>
        <anchor id="ch0065s000001a0003"/>
        <anchor id="ch0065s000000a0003"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0002">
      <title>Bordetella</title>
      <anchor id="ch0065s000002a0001"/>
      <anchor id="ch0065s000000a0004"/>
      <para id="ch0065s000000p0003">The genome sizes of members of this genus ranges from 3.7 Mbp to 5.3 Mbp (4.086 Mbp for<emphasis>B. pertussis</emphasis>, 4.774 Mbp for <emphasis>B. parapertussis</emphasis>, 5.338 Mbp for <emphasis>B. bronchiseptica</emphasis>, 5.287 Mbp for <emphasis>B. petrii</emphasis>, 3.732 Mbp for <emphasis>B. avium</emphasis>, and ~3.8 Mbp for <emphasis>B. holmesii</emphasis>). Insertion sequences are mainly found in the genomes of <emphasis>B. pertussis</emphasis> (IS<emphasis>481</emphasis> and IS<emphasis>1002</emphasis>), <emphasis>B. parapertussis</emphasis> (IS<emphasis>1001</emphasis>), and <emphasis>B. holmesii</emphasis> (IS<emphasis>481</emphasis> and IS<emphasis>1001</emphasis>-like) and less often in <emphasis>B. bronchiseptica</emphasis> (<link linkend="ch0065s000000li0007">7</link>, <link linkend="ch0065s000000li0020">20</link>, <link linkend="ch0065s000000li0021">21</link>). A comparison between the species reveals that only around 50% of the genome is conserved in all species and that multiple mechanisms, such as gain or loss of genes, point mutations, and horizontal gene transfer, may play a role in the development of the species (<link linkend="ch0065s000000li0022">22</link>). Analysis of virulence genetic changes demonstrates that specific changes in O antigens, protein secretion systems, and bacterial toxins are occurring across <emphasis>Bordetella</emphasis> clades, species, and strains and that these changes may lead to alterations in the genes encoding for pertussis vaccine components (<link linkend="ch0065s000000li0023">23</link>).</para>
      <para id="ch0065s000000p0004">Bordetellae are catalase positive and oxidize amino acids, but no carbohydrates are fermented. Some species possess uniformly distributed flagella and are motile. Bordetellae are generally able to grow in simple synthetic media under aerobic conditions (except<emphasis>B. petrii</emphasis>; see below). However, <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> are sensitive to toxic substances and metabolites present in many microbiological media and need special transport conditions, special culture media, and prolonged incubation. The other species can be isolated by routine microbiological procedures.</para>
      <para id="ch0065s000000p0005"><emphasis>B. petrii</emphasis> is the most versatile <emphasis>Bordetella</emphasis> species; it can grow aerobically and anaerobically and was initially found as a free-living environmental bacterium (<link linkend="ch0065s000000li0021">21</link>). All other bordetellae are found only in warm-blooded animals and humans. <emphasis>B. avium</emphasis> is a pathogen of poultry and has only once been isolated from humans. <emphasis>B. bronchiseptica</emphasis> can cause respiratory infections in many animal species and infrequently in humans. <emphasis>B. holmesii</emphasis> is recognized as a pathogen mostly in immunosuppressed individuals but also in immunocompetent patients and may cause a variety of systemic diseases in various organ systems (<link linkend="ch0065s000000li0024">24</link>, <link linkend="ch0065s000000li0025">25</link>). <emphasis>B. ansorpii, B. hinzii, B. petrii</emphasis>, and <emphasis>B. trematum</emphasis> rarely cause human infections and are mainly reported in immunocompromised patients. <emphasis>B. parapertussis</emphasis> has been found in sheep and humans, while <emphasis>B. pertussis</emphasis> is thought to be strictly a human pathogen (<anchor id="ch0065s000000a0006"/><link linkend="ch0065s000000a0007">Table 1</link>).</para>
      <anchor id="ch0065s000000a0005"/>
      <beginpage pagenum="945"/>
      <table id="ch0065s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0065s000000a0007"/><link linkend="ch0065s000000a0006">TABLE 1</link></phrase></emphasis> Members of the genus <emphasis>Bordetella</emphasis>
</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><phrase role="left">Species</phrase>
              </entry>
              <entry><phrase role="left">Host</phrase>
              </entry>
              <entry><phrase role="left">Disease</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. avium</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Poultry</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. bronchialis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease (cystic fibrosis)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. bronchiseptica</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Animals</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease, systemic infection (immunocompromised hosts)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. flabilis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease (cystic fibrosis)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. hinzii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Poultry</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Cholangitis, arthritis</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease, systemic infection (immunocompromised hosts)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. muralis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Environment</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. parapertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Parapertussis (pertussis-like disease)</phrase>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Sheep</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Pertussis</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. petrii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Environment</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Osteomyelitis, mastoiditis</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. pseudohinzii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Mice</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. sputigena</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Respiratory disease (cystic fibrosis)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. trematum</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Wound infection, otitis</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. tumbae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Environmental</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. tumulicola</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Environment</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">“<emphasis>B. ansorpii</emphasis>”</phrase>
              </entry>
              <entry><phrase role="left">Humans</phrase>
              </entry>
              <entry><phrase role="left">Epidermal cyst, systemic infection (immunocompromised hosts)</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para id="ch0065s000000p0006">Bordetellae express several virulence factors controlled by a complex virulence expression system operating in response to environmental conditions (<emphasis>Bvg</emphasis>AS) (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0026">26</link>), changing between mode X (respiratory tract infection), mode I (intermediate, possibly relevant for transmission), and mode C (starvation). Virulence factors can be classified as adhesins, autotransporters (e.g., filamentous hemagglutinin, fimbriae, and pertactin), and toxins (e.g., pertussis toxin [PT], adenylate cyclase hemolysin, and lipopolysaccharide) (<link linkend="ch0065s000000li0002">2</link>). Only <emphasis>B. pertussis</emphasis> produces PT, encoded by the <emphasis>ptx</emphasis> gene, whereas <emphasis>B. parapertussis</emphasis> and <emphasis>B. bronchiseptica</emphasis> contain the <emphasis>ptx</emphasis> gene but normally lack the promoter (<link linkend="ch0065s000000li0002">2</link>). PT has ADP-ribosyltransferase activity and ribosylates G(i) proteins, thereby suppressing chemotaxis, oxidative responses, and the overall activity of neutrophils and macrophages. Filamentous hemagglutinin is a large (220-kDa) surface-associated and -secreted protein and mediates the adhesion of the bordetellae to the ciliated epithelium of the upper respiratory tract. Filamentous hemagglutinin is produced by <emphasis>B. pertussis, B. parapertussis</emphasis>, and <emphasis>B. bronchiseptica</emphasis> (<link linkend="ch0065s000000li0002">2</link>). Type 2 and 3 fimbriae (FIM2 and FIM3) are important factors in colonizing the respiratory mucosa. Isolates of <emphasis>B. pertussis</emphasis> can display FIM2, FIM3, or both on their surfaces. Adenylate cyclase hemolysin is a hemolysin with enzymatic activity (<link linkend="ch0065s000000li0027">27</link>). <emphasis>B. pertussis</emphasis> also produces a lipopolysaccharide without a repetitive O-antigenic chain. Pertactin is a 68- to 70-kDa surface protein that mediates eukaryotic cell binding <emphasis>in vitro</emphasis> (<link linkend="ch0065s000000li0002">2</link>), is involved in cell attachment, and is highly immunogenic (<link linkend="ch0065s000000li0028">28</link>). Notably, in recent years, isolates not expressing pertactin have been found in many countries with increasing frequency. The clinical presentation appears similar for pertactin-positive and -negative strains (<link linkend="ch0065s000000li0029">29</link>–<link linkend="ch0065s000000li0031">31</link>). <emphasis>B. pertussis, B. parapertussis</emphasis>, and <emphasis>B. bronchiseptica</emphasis> share virulence genes as well, including those encoding the type III secretion system and the <emphasis>Bordetella</emphasis>-secreted protein regulator (BspR), a conserved protein across species (<link linkend="ch0065s000000li0032">32</link>).</para>
    </sect1>
    <sect1 id="ch0065s0003">
      <title>Achromobacter</title>
      <anchor id="ch0065s000003a0001"/>
      <anchor id="ch0065s000000a0008"/>
      <para id="ch0065s000000p0007"><emphasis>Achromobacter</emphasis> species are Gram-negative, nonsporulating, small bacilli. Most species are motile, but motility is weak or absent in <emphasis>A. pulmonis</emphasis> and is strain dependent in <emphasis>A. insuavis. Achromobacter</emphasis> species are strictly aerobic and nonfermentative, although strains of some species are able to grow anaerobically with nitrate as an electron acceptor (<link linkend="ch0065s000000li0010">10</link>). All <emphasis>Achromobacter</emphasis> species are oxidase and catalase positive, but none of them exhibit DNase, lysine decarboxylase, ornithine decarboxylase, arginine dihydrolase, or gelatinase activity (<link linkend="ch0065s000000li0009">9</link>–<link linkend="ch0065s000000li0011">11</link>, <link linkend="ch0065s000000li0013">13</link>). Urease activity was reported only in <emphasis>A. aloeverae. Achromobacter</emphasis> species grow well on simple media, and colonies on nutrient agar are flat or slightly convex with smooth margins and range from white to light brown (<link linkend="ch0065s000000li0009">9</link>). Under laboratory conditions, growth occurs between 30 and 37°C and in the presence of 0 to 1.5% NaCl (<link linkend="ch0065s000000li0009">9</link>, <link linkend="ch0065s000000li0010">10</link>, <link linkend="ch0065s000000li0033">33</link>). Several <emphasis>Achromobacter</emphasis> species contain the Q-8 ubiquinone system (<link linkend="ch0065s000000li0001">1</link>). Although detailed information about the natural habitat of these organisms is lacking, soil and water are considered the primary sources of infection (<link linkend="ch0065s000000li0001">1</link>).</para>
    </sect1>
    <sect1 id="ch0065s0004">
      <title>Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000004a0001"/>
      <anchor id="ch0065s000000a0009"/>
      <para id="ch0065s000000p0008">Following many taxonomic revisions, the genus<emphasis>Alcaligenes</emphasis> is now limited to <emphasis>A. faecalis</emphasis> (with three subspecies: <emphasis>A. faecalis</emphasis> subsp. <emphasis>faecalis, A. faecalis</emphasis> subsp. <emphasis>parafaecalis</emphasis>, and <emphasis>A. faecalis</emphasis> subsp. <emphasis>phenolicus</emphasis>), <emphasis>A. aquatilis, A. endophyticus</emphasis>, and <emphasis>A. pakistanensis. A. faecalis</emphasis> subsp. <emphasis>parafaecalis, A. faecalis</emphasis> subsp. <emphasis>phenolicus, A. aquatilis, A. endophyticus</emphasis>, and <emphasis>A. pakistanensis</emphasis> are represented by environmental isolates only. Some <emphasis>A. faecalis</emphasis> strains produce a characteristic fruity odor and/or cause a greenish discoloration of blood agar medium; these strains were previously referred to as “<emphasis>A. odorans.</emphasis>” <emphasis>Alcaligenes</emphasis> species are Gram-negative, strictly aerobic rods or coccobacilli that possess oxidase and catalase activity (<link linkend="ch0065s000000li0001">1</link>). Cells are motile by means of 1 to 12 uniformly distributed flagella. The optimum growth temperature is between 20 and 37°C. They grow well on simple media, and colonies on nutrient agar are generally nonpigmented.</para>
      <anchor id="ch0065s000000a0010"/>
      <beginpage pagenum="946"/>
      <para id="ch0065s000000p0009">Cells of<emphasis>Kerstersia</emphasis> and <emphasis>Advenella</emphasis> species are Gram negative, small (1 to 2 μm), and rod-shaped or coccoid and occur alone, in pairs, or in short chains. Motility is strain dependent. They grow well on simple media. On nutrient agar, colonies are flat or slightly convex with smooth margins and range from white to light brown. They are strictly aerobic and nonfermentative. All isolates studied so far are catalase positive, while none exhibit β-galactosidase activity (<link linkend="ch0065s000000li0008">8</link>, <link linkend="ch0065s000000li0016">16</link>). <emphasis>Kerstersia</emphasis> strains can grow between 28 and 42°C; growth also occurs with up to 4.5% NaCl. Predominant fatty acids in <emphasis>Kerstersia</emphasis> species are C<subscript>16:0</subscript> and C<subscript>17:0 cyclo</subscript> (<link linkend="ch0065s000000li0008">8</link>). <emphasis>Advenella</emphasis> strains can grow at between 30 and 37°C and at NaCl concentrations between 0 and 3%.</para>
      <para id="ch0065s000000p0010">Cells from<emphasis>Paenalcaligenes</emphasis> species are Gram-negative, small (1- to 2-μm) rods. They grow well on nutrient agar at 25 to 30°C and are oxidase positive. Sugars and sugar-related compounds are not utilized.</para>
      <sect2 id="ch0065s0004s0001">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0065s000004a0002"/>
        <anchor id="ch0065s000000a0011"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0005">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000005a0001"/>
      <anchor id="ch0065s000000a0012"/>
      <para id="ch0065s000000p0011"><emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> are transmitted via respiratory droplets, and for <emphasis>B. pertussis</emphasis> in susceptible contacts, the transmission rate may approach 90% with an infectious dose as low as 100 CFU (<link linkend="ch0065s000000li0002">2</link>). <emphasis>B. pertussis</emphasis> has shown to occur more frequently during the summer and autumn months in the United States, Germany, and the Netherlands (<link linkend="ch0065s000000li0034">34</link>, <link linkend="ch0065s000000li0035">35</link>). In Australia, studies of seasonal variation suggest pertussis peaks have occurred from late winter to early summer (<link linkend="ch0065s000000li0036">36</link>). In addition, although data from tropical and subtropical areas are more limited, surveillance reports from Senegal and Kenya suggest that <emphasis>B. pertussis</emphasis> transmission may be higher during cooler, dry months of the year (<link linkend="ch0065s000000li0034">34</link>). The bacteria attach to ciliated cells lining the nasopharynx and subsequently colonize the upper respiratory tract. <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> are the cause of pertussis, or whooping cough. Infections by <emphasis>B. parapertussis</emphasis> tend to take a milder clinical course with a shorter duration of coughing and less vomiting and whooping than that of <emphasis>B. pertussis</emphasis> (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0037">37</link>–<link linkend="ch0065s000000li0040">40</link>). Globally, among children less than 5 years of age, pertussis is estimated to cause 24.1 million hospitalizations and 160,700 deaths each year, with the largest proportion of these occurring in Africa (<link linkend="ch0065s000000li0041">41</link>). It is assumed that the disease is grossly underreported due to underrecognition by clinicians, underuse of diagnostic testing, infected patients not seeking medical attention, and limitations in disease reporting through surveillance systems (<link linkend="ch0065s000000li0042">42</link>). <emphasis>B. pertussis</emphasis> also continues to circulate in populations where high vaccination coverage of infants and children is achieved, because the protection after natural infection and vaccination wanes after several years (<link linkend="ch0065s000000li0039">39</link>, <link linkend="ch0065s000000li0043">43</link>).</para>
      <para id="ch0065s000000p0012"><emphasis>B. parapertussis</emphasis> causes a whooping cough-like illness, and recent data suggest that current pertussis vaccines may elicit cross-protective antibodies against <emphasis>B. parapertussis</emphasis> in infants and children (<link linkend="ch0065s000000li0044">44</link>). In vaccinating countries, cases of pertussis are now mainly observed in neonates, unvaccinated young infants, older schoolchildren, adolescents, and adults (<link linkend="ch0065s000000li0038">38</link>, <link linkend="ch0065s000000li0039">39</link>, <link linkend="ch0065s000000li0043">43</link>, <link linkend="ch0065s000000li0045">45</link>, <link linkend="ch0065s000000li0046">46</link>). A permanent carrier state is not found in pertussis, although in outbreak situations asymptomatic transient carriage of <emphasis>Bordetella</emphasis> DNA detected by PCR has been observed (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0040">40</link>). In vaccinated European populations, the basic reproduction number was estimated to be 5.5 (<link linkend="ch0065s000000li0047">47</link>), and transmission mainly occurs from adolescents and adults to infants or among older vaccinated children, adolescents, and adults (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0038">38</link>). Neonates and young infants are at greatest risk of being infected by their parents, although casual contacts may be important (<link linkend="ch0065s000000li0048">48</link>). In various countries, such as Australia, Brazil, the United States, and the United Kingdom, significant increases in notified cases have occurred in recent years, and various factors (e.g., structural changes in circulating strains, waning immunologic protection after immunization with acellular vaccines, low vaccine coverage, changes in vaccination schedules, more effective diagnostics, and differences in immunologic priming) have been hypothesized as being responsible for the outbreaks (<link linkend="ch0065s000000li0049">49</link>, <link linkend="ch0065s000000li0050">50</link>). Several countries have implemented pertussis immunization during pregnancy, and reports suggest that such programs may reduce pertussis rates, hospitalizations, and mortality among infants (<link linkend="ch0065s000000li0051">51</link>–<link linkend="ch0065s000000li0053">53</link>).</para>
    </sect1>
    <sect1 id="ch0065s0006">
      <title>Other Bordetella Species, Achromobacter, Alcaligenes, Kerstersia, and Advenella</title>
      <anchor id="ch0065s000006a0001"/>
      <anchor id="ch0065s000000a0013"/>
      <para id="ch0065s000000p0013">Among the bordetellae,<emphasis>B. holmesii</emphasis> (<link linkend="ch0065s000000li0005">5</link>, <link linkend="ch0065s000000li0024">24</link>) is increasingly found mainly by PCR tests primarily using IS<emphasis>481</emphasis> as a target, which shares homogeneity between <emphasis>B. pertussis, B. holmesii</emphasis>, and other bordetellae (<anchor id="ch0065s000000a0014"/><link linkend="ch0065s000000a0019">Tables 2</link> and <anchor id="ch0065s000000a0015"/><link linkend="ch0065s000000a0020">3</link>) (<link linkend="ch0065s000000li0054">54</link>, <link linkend="ch0065s000000li0055">55</link>).</para>
      <para id="ch0065s000000p0014">Data on epidemiology and transmission are limited to<emphasis>Achromobacter</emphasis> infections in cystic fibrosis (CF) patients. Persistent infections with <emphasis>A. xylosoxidans</emphasis> can occur, because genotypically identical isolates are recovered from the respiratory tract over prolonged periods of time (<link linkend="ch0065s000000li0056">56</link>–<link linkend="ch0065s000000li0059">59</link>). There have been several reports of multiple CF patients being colonized or infected by the same <emphasis>A. xylosoxidans</emphasis> isolate (<link linkend="ch0065s000000li0057">57</link>–<link linkend="ch0065s000000li0061">61</link>). Both patient-to-patient transmission and acquisition from the environment have been proposed as explanations for the spread of certain strains among CF patients (<link linkend="ch0065s000000li0058">58</link>, <link linkend="ch0065s000000li0062">62</link>). The “Danish epidemic strain” was identified as <emphasis>A. ruhlandii</emphasis> (<link linkend="ch0065s000000li0063">63</link>). This strain has infected multiple patients in two Danish CF centers, and cross-infection was documented to also occur by indirect patient-to-patient contact (<link linkend="ch0065s000000li0064">64</link>).</para>
      <sect2 id="ch0065s0006s0001">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0065s000006a0002"/>
        <anchor id="ch0065s000000a0016"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0007">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000007a0001"/>
      <anchor id="ch0065s000000a0017"/>
      <para id="ch0065s000000p0015">After a typical incubation period of 7 to 10 days (range, 4 to 28 days), the primary infection starts with rhinorrhea, sneezing, and nonspecific coughs (catarrhal phase). Clinical signs and symptoms of pertussis are found in primary infections of nonvaccinated children, with coughing spasms, audible whooping, and vomiting (paroxysmal phase) (<link linkend="ch0065s000000li0039">39</link>, <link linkend="ch0065s000000li0065">65</link>). Cases in neonates and unvaccinated young infants often present with apnea as the only clinical sign (<link linkend="ch0065s000000li0002">2</link>, <link linkend="ch0065s000000li0043">43</link>, <link linkend="ch0065s000000li0066">66</link>). In older schoolchildren, adolescents, and adults, clinical signs and symptoms can vary widely. Adult pertussis may be associated with an acute cough (i.e., &lt;3 weeks in duration) or subacute cough (3 to 8 weeks) in which clinicians should assess the four characteristics of paroxysmal cough, posttussive vomiting, inspiratory whooping, and absence of fever when ruling in or out a clinical diagnosis of pertussis (<link linkend="ch0065s000000li0067">67</link>). Even in the absence of paroxysms, a cough with a duration of more than 3 weeks should lead to suspicion of pertussis. Coughing is frequently accompanied by choking, vomiting, and whooping (<link linkend="ch0065s000000li0038">38</link>). The U.S. CDC/CSTE (Council of State and Territorial Epidemiologists) surveillance case defines pertussis (<ulink url="https://ndc.services.cdc.gov/case-definitions/pertussis-2020/">https://ndc.services.cdc.gov/case-definitions/pertussis-2020/</ulink>) by the presence of a cough lasting ≥2 weeks with at least one of the following signs or symptoms: paroxysms of coughing, inspiratory whoop, posttussive vomiting, and apnea (with or without cyanosis). Confirmatory laboratory evidence is determined by isolation of <emphasis>B. pertussis</emphasis> from a clinical specimen or positive PCR for <emphasis>B. pertussis.</emphasis> The disease is most dangerous in infants, and most hospitalizations and deaths occur in this age group. Fatal cases of the disease may go undetected in young infants (<link linkend="ch0065s000000li0043">43</link>, <link linkend="ch0065s000000li0068">68</link>). Pertussis-like symptoms may also be caused by adenoviruses, respiratory syncytial virus, human parainfluenza viruses, influenza viruses, <emphasis>Mycoplasma pneumoniae</emphasis>, and other agents (<link linkend="ch0065s000000li0043">43</link>, <link linkend="ch0065s000000li0069">69</link>).</para>
      <anchor id="ch0065s000000a0018"/>
      <beginpage pagenum="947"/>
      <table id="ch0065s000000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0065s000000a0019"/><link linkend="ch0065s000000a0014">TABLE 2</link></phrase></emphasis> Possible targets for detection of <emphasis>Bordetella</emphasis> DNA by real-time PCR
</title>
        
        <tgroup cols="4">
          <tbody>
            <row>
              <entry><phrase role="left">Target</phrase>
              </entry>
              <entry><phrase role="left">Species containing target</phrase>
              </entry>
              <entry><phrase role="center">Copy number per genome</phrase>
              </entry>
              <entry><phrase role="center">Comments</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">IS<emphasis>481</emphasis></phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">~200</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="center">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">~10</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="center">
                  <emphasis>B. bronchiseptica</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">&lt;5</phrase>
              </entry>
              <entry><phrase role="center">&lt;1% of isolates</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">IS<emphasis>1001</emphasis></phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. parapertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">~20</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry/>
              <entry><phrase role="center">
                  <emphasis>B. bronchiseptica</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">&lt;5</phrase>
              </entry>
              <entry><phrase role="center">~50% of isolates</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">IS<emphasis>1002</emphasis></phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">~10</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry/>
              <entry><phrase role="center">
                  <emphasis>B. parapertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">&lt;<emphasis>5</emphasis></phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">hIS<emphasis>1001</emphasis></phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
              <entry/>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>ptxP</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">1</phrase>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>recA</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">1</phrase>
              </entry>
              <entry/>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0065s000000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0065s000000a0020"/><link linkend="ch0065s000000a0015">TABLE 3</link></phrase></emphasis> Possible results of <emphasis>Bordetella</emphasis> PCR and suggested interpretation
</title>
        
        <tgroup cols="6">
          <tbody>
            <row>
              <entry><phrase role="center">Result with target<superscript><emphasis><anchor id="ch0065s000000a0021"/><link linkend="ch0065s000000a0022">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Species to report</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">IS<emphasis>481</emphasis></phrase>
              </entry>
              <entry><phrase role="center">IS<emphasis>1001</emphasis></phrase>
              </entry>
              <entry><phrase role="center">IS<emphasis>1002</emphasis></phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>ptxP</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>recA</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Bordetella</emphasis> species</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Neg</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>B. parapertussis</emphasis>
                </phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Neg</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Bordetella</emphasis> species</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pos</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Neg</phrase>
              </entry>
              <entry><phrase role="center">Pos</phrase>
              </entry>
              <entry><phrase role="left">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0065s000000a0022"/><link linkend="ch0065s000000a0021">a</link></emphasis></superscript>Pos, positive; neg, negative.</para>
    </sect1>
    <sect1 id="ch0065s0008">
      <title>Other Bordetella Species</title>
      <anchor id="ch0065s000008a0001"/>
      <anchor id="ch0065s000000a0023"/>
      <para id="ch0065s000000p0016">Due to more frequent diagnosis,<emphasis>B. holmesii</emphasis> (<link linkend="ch0065s000000li0005">5</link>, <link linkend="ch0065s000000li0070">70</link>) is suspected to be a pathogen that may cause respiratory symptoms in adolescents and adults (<link linkend="ch0065s000000li0054">54</link>, <link linkend="ch0065s000000li0055">55</link>) and inflammation in various organs in immunocompromised patients. Cases of a pertussis-like illness caused by <emphasis>B. holmesii</emphasis> have been reported from all over the world (<link linkend="ch0065s000000li0025">25</link>, <link linkend="ch0065s000000li0055">55</link>, <link linkend="ch0065s000000li0071">71</link>). In a study from Spain, the prevalence of <emphasis>B. holmesii</emphasis> infections increased from 3.9% in 2015 to 8.8% in 2016 (<link linkend="ch0065s000000li0071">71</link>). <emphasis>B. bronchiseptica, B. petrii, B. avium, B. ansorpii</emphasis>, and <emphasis>B. hinzii</emphasis> are rarely isolated from respiratory materials from patients with respiratory symptoms. In many cases, patients are systemically or locally immunocompromised. As with other Gram-negative nonfermentative bacilli, cases of bacteremia, septicemia, and other invasive manifestations have been described. Other species are less often reported. <emphasis>B. trematum</emphasis> has been isolated from poultry industry workers, and there are recent case reports from patients with lung cancer (respiratory tract) (<link linkend="ch0065s000000li0072">72</link>) and with congestive dermatitis (leg wound) (<link linkend="ch0065s000000li0073">73</link>); <emphasis>B. ansorpii</emphasis> has been reported as a rare cause of septicemia. <emphasis>B. petrii</emphasis> and possibly other environmental bordetellae are rarely found in clinical material, and <emphasis>B. avium</emphasis> has so far been isolated only once from respiratory material from humans.</para>
    </sect1>
    <sect1 id="ch0065s0009">
      <title>Achromobacter</title>
      <anchor id="ch0065s000009a0001"/>
      <anchor id="ch0065s000000a0024"/>
      <para id="ch0065s000000p0017">Many<emphasis>Achromobacter</emphasis> species have been recovered from clinical samples or from the hospital environment. <emphasis>A. xylosoxidans</emphasis> is an opportunistic human pathogen capable of causing a wide range of infections, such as bacteremia, meningitis, pneumonia, and peritonitis (<link linkend="ch0065s000000li0074">74</link>, <link linkend="ch0065s000000li0075">75</link>). It has also been found to be involved in nosocomial infections attributed to contaminated disinfectants, dialysis fluids, saline solution, and water (<link linkend="ch0065s000000li0076">76</link>). <emphasis>A. piechaudii</emphasis> has been isolated from various clinical samples, including pharyngeal swab, nose, wound, blood, and chronic ear discharge (<link linkend="ch0065s000000li0077">77</link>). <emphasis>A. denitrificans</emphasis> (previously known as <emphasis>A. xylosoxidans</emphasis> subsp. <emphasis>denitrificans</emphasis>) has been recovered from many clinical specimens, such as urine, proctoscopy specimens, prostate secretions, the buccal cavity, pleural fluid, and eye swabs, but there are no detailed reports about its clinical significance. <emphasis>A. insolitus</emphasis> (in a leg wound and in urine) and <emphasis>A. spanius</emphasis> (in blood) have been found in clinical material, but their significance is unclear (<link linkend="ch0065s000000li0009">9</link>). Strains of <emphasis>A. aegrifaciens, A. animicus, A. anxifer, A. dolens, A. insuavis, A. marplatensis, A. mucicolens</emphasis>, and <emphasis>A. pulmonis</emphasis> have mainly been recovered from sputum of CF patients, but their clinical significance remains unclear (<link linkend="ch0065s000000li0010">10</link>, <link linkend="ch0065s000000li0011">11</link>).</para>
      <anchor id="ch0065s000000a0025"/>
      <beginpage pagenum="948"/>
      <para id="ch0065s000000p0018"><emphasis>Achromobacter</emphasis> spp. are frequently associated with CF. <emphasis>A. xylosoxidans</emphasis> isolates have been reported from CF patients since 1985, and prevalence rates in CF were estimated to range from 3 to 18% (<link linkend="ch0065s000000li0062">62</link>, <link linkend="ch0065s000000li0078">78</link>–<link linkend="ch0065s000000li0080">80</link>). However, recent studies based on multilocus sequence analysis and/or sequencing of the <emphasis>nrdA</emphasis> gene indicate that patients with CF are often infected with <emphasis>Achromobacter</emphasis> species other than <emphasis>A. xylosoxidans</emphasis> (<link linkend="ch0065s000000li0011">11</link>, <link linkend="ch0065s000000li0063">63</link>, <link linkend="ch0065s000000li0081">81</link>, <link linkend="ch0065s000000li0082">82</link>). Among 341 <emphasis>Achromobacter</emphasis> species-infected CF patients in the United States, 42% were infected with <emphasis>A. xylosoxidans</emphasis>, and a retrospective analysis (for the period from 1984 to 2013) revealed that 50% of <emphasis>Achromobacter</emphasis>-positive patients attending a Canadian CF clinic were colonized with <emphasis>A. xylosoxidans</emphasis> (<link linkend="ch0065s000000li0083">83</link>). A high prevalence of <emphasis>A. xylosoxidans</emphasis> (38% and 36%) was also reported in two studies on Danish <emphasis>Achromobacter</emphasis> species-infected CF patients (<link linkend="ch0065s000000li0084">84</link>, <link linkend="ch0065s000000li0085">85</link>) and in studies involving CF patients from France (<link linkend="ch0065s000000li0062">62</link>) and the United Kingdom (<link linkend="ch0065s000000li0086">86</link>). Other <emphasis>Achromobacter</emphasis> species frequently recovered from CF patients include <emphasis>A. insuavis, A. dolens, A. ruhlandii</emphasis>, and <emphasis>A. aeg</emphasis><emphasis>rifaciens</emphasis>.</para>
      <para id="ch0065s000000p0019"><emphasis>A. xylosoxidans</emphasis> infections in CF patients do not seem to have a significant impact on lung function (<link linkend="ch0065s000000li0060">60</link>, <link linkend="ch0065s000000li0078">78</link>, <link linkend="ch0065s000000li0087">87</link>). A recent study indicated that overall, <emphasis>Achromobacter</emphasis> species infections are associated with increased risk of pulmonary exacerbations, but this does not seem to affect long-term prognosis (<link linkend="ch0065s000000li0083">83</link>). However, infection with the <emphasis>A. ruhlandii</emphasis> Danish epidemic strain can lead to deterioration of lung function (<link linkend="ch0065s000000li0064">64</link>), and colonization with <emphasis>A. ruhlandii</emphasis> was found to be associated with increased risk of chronic infection (<link linkend="ch0065s000000li0085">85</link>).</para>
    </sect1>
    <sect1 id="ch0065s0010">
      <title>Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000010a0001"/>
      <anchor id="ch0065s000000a0026"/>
      <para id="ch0065s000000p0020"><emphasis>A. faecalis</emphasis> strains have been isolated from a wide range of clinical samples, but the accuracy of the identification (especially in older reports) is difficult to assess. <emphasis>A. faecalis</emphasis> was found in cases of bacteremia following surgery or cancer treatment, from ocular infections, from a pancreatic abscess, from infections following bone fractures, from urine, and from ear discharge (<link linkend="ch0065s000000li0077">77</link>). There are sporadic reports of the recovery of <emphasis>A. faecalis</emphasis> in sputum of CF patients (<link linkend="ch0065s000000li0088">88</link>). <emphasis>K. gyiorum</emphasis> was isolated from human feces, leg wounds, sputum, urine, and chronic ear infections (<link linkend="ch0065s000000li0008">8</link>, <link linkend="ch0065s000000li0073">73</link>), while <emphasis>K. similis</emphasis> was isolated from leg wounds and a neck abscess (<link linkend="ch0065s000000li0089">89</link>). <emphasis>A. incenata</emphasis> has been recovered from human sputum (including sputum from CF patients) and blood, and several unnamed <emphasis>Advenella</emphasis> species were isolated from similar sources (<link linkend="ch0065s000000li0016">16</link>). The two <emphasis>P. hominis</emphasis> strains described so far were recovered from blood and urine (<link linkend="ch0065s000000li0018">18</link>).</para>
      <sect2 id="ch0065s0010s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0065s000010a0002"/>
        <anchor id="ch0065s000000a0027"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0011">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000011a0001"/>
      <anchor id="ch0065s000000a0028"/>
      <para id="ch0065s000000p0021">Clinical sample collection for culture and PCR testing may be challenging depending on the patient’s age and clinical condition, yet the collection technique can significantly impact test sensitivity. Nasopharyngeal (NP) aspirates are optimal samples for collection among infants and young children, and for culture, they are more sensitive than swabs (<ulink url="http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html">http://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html</ulink>; <ulink url="https://www.ecdc.europa.eu/en/publications-data/guidance-and-protocol-use-real-time-pcr-laboratory-diagnosis-human-infection">https://www.ecdc.europa.eu/en/publications-data/guidance-and-protocol-use-real-time-pcr-laboratory-diagnosis-human-infection</ulink>). In older children, adolescents, and adults, posterior NP swabs provide valid specimens and are better than throat swabs. NP swabs should be taken by gently inserting the swab into the posterior nasopharynx under the inferior nasal choana, and the nose of the patient should be slightly bent upward. If possible, two NP swabs should be taken (one for culture and one for PCR), but one swab (to be used for culture and PCR) is also acceptable (<ulink url="https://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html">https://www.cdc.gov/pertussis/clinical/diagnostic-testing/specimen-collection.html</ulink>). Swabs should be small and made of Dacron or rayon. Flocked nylon swabs, which are more convenient for the patient, may also be used but have not been validated for <emphasis>B. pertussis</emphasis> PCR or culture. Cotton-tipped or calcium-alginate swabs and swabs with aluminum shafts should not be used for PCR testing because they may inhibit PCRs (<link linkend="ch0065s000000li0090">90</link>). Samples should be collected prior to initiation of antibiotic treatment (<link linkend="ch0065s000000li0091">91</link>).</para>
      <para id="ch0065s000000p0022">For NP aspirates or swabs, transport time is critical, and a transport medium protecting the bacteria from drying is required. Usual bacteriological transport media, such as Casamino Acids or Amies medium with charcoal, may be used, but transport time should not exceed 48 h. Half-strength Regan-Lowe (RL) charcoal-blood medium may also be used for transport, and it serves as enrichment for<emphasis>B. pertussis</emphasis>.</para>
      <para id="ch0065s000000p0023">For PCR, swabs can be transported dry at ambient temperature. The use of microbiological transport media, such as Amies medium with charcoal, does not interfere with PCR (<link linkend="ch0065s000000li0091">91</link>). Other respiratory samples, such as sputum samples and throat washes, are less suitable (<link linkend="ch0065s000000li0002">2</link>).</para>
    </sect1>
    <sect1 id="ch0065s0012">
      <title>Other Bordetella Species, Achromobacter, Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000012a0001"/>
      <anchor id="ch0065s000000a0029"/>
      <para id="ch0065s000000p0024">For other bordetellae, normal microbiological transport media seem suitable for transport. Similarly,<emphasis>Alcaligenes, Kerstersia, Advenella</emphasis>, and <emphasis>Paenalcaligenes</emphasis> species can survive in a wide range of environments and at various temperatures. Standard collection, transport, and storage techniques are sufficient to ensure recovery of these organisms from clinical specimens, contaminated nosocomial sources, and the environment.</para>
      <sect2 id="ch0065s0012s0001">
        <title>DIRECT EXAMINATION</title>
        <anchor id="ch0065s000012a0002"/>
        <anchor id="ch0065s000000a0030"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0013">
      <title>Nucleic Acid Detection</title>
      <anchor id="ch0065s000013a0001"/>
      <anchor id="ch0065s000000a0031"/>
      <para id="ch0065s000000p0025">PCR is 2- to 6-fold more sensitive than culture, depending on the patients’ age, vaccination status, and duration of symptoms. Real-time PCR formats offer a result within several hours instead of several days (<link linkend="ch0065s000000li0091">91</link>–<link linkend="ch0065s000000li0093">93</link>). Block-based and real-time PCR provide comparable sensitivity (<link linkend="ch0065s000000li0091">91</link>, <link linkend="ch0065s000000li0094">94</link>, <link linkend="ch0065s000000li0095">95</link>). The sensitivity of PCR decreases as cough duration increases; however, due to higher sensitivity of PCR, it may be a useful tool for diagnosis in patients with up to 4 to 6 weeks of coughing (<link linkend="ch0065s000000li0091">91</link>, <link linkend="ch0065s000000li0093">93</link>). In outbreak situations, PCR may detect pertussis transmission among household contacts with very few or no symptoms (<link linkend="ch0065s000000li0096">96</link>). DNA extraction may be necessary to limit inhibition of PCR (<link linkend="ch0065s000000li0091">91</link>). Commercially available extraction kits seem to be comparable and appropriate (<link linkend="ch0065s000000li0091">91</link>), but no head-to-head comparison has been done. Some of these kits are FDA cleared and/or CE marked for this purpose. Multicopy targets for detection are IS<emphasis>481</emphasis> (copy number, ~200 per cell in <emphasis>B. pertussis</emphasis>) (<link linkend="ch0065s000000li0038">38</link>, <link linkend="ch0065s000000li0093">93</link>), which is present in <emphasis>B. pertussis, B. holmesii</emphasis>, and some <emphasis>B. bronchiseptica</emphasis> strains; IS<emphasis>1001</emphasis> (copy number, ~20 per cell in <emphasis>B. parapertussis</emphasis>) (<link linkend="ch0065s000000li0097">97</link>), which is present in <emphasis>B. parapertussis</emphasis>; and IS<emphasis>1002</emphasis>, which is present in <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis.</emphasis> The combined use of the three ISs has been suggested to distinguish clinically relevant <emphasis>Bordetella</emphasis> species (<link linkend="ch0065s000000li0098">98</link>) and to distinguish <emphasis>B. holmesii</emphasis> (<link linkend="ch0065s000000li0099">99</link>). In current isolates, the number of ISs remained stable compared to those in the sequenced type strains (<link linkend="ch0065s000000li0097">97</link>). Monogenic targets include the PT promoter (<emphasis>ptxA</emphasis>-Pr), the PT gene, the <emphasis>recA</emphasis> gene from <emphasis>B. holmesii</emphasis>, and the filamentous hemagglutinin and the porin gene. Targets are summarized in <link linkend="ch0065s000000a0019">Table 2</link> (<link linkend="ch0065s000000li0091">91</link>–<link linkend="ch0065s000000li0093">93</link>, <link linkend="ch0065s000000li0098">98</link>–<link linkend="ch0065s000000li0101">101</link>).</para>
      <anchor id="ch0065s000000a0032"/>
      <beginpage pagenum="949"/>
      <para id="ch0065s000000p0026">Tests detecting single-copy genes are, however, consistently less sensitive than IS<emphasis>481-</emphasis>based PCRs. Detection can be performed using a sequence-specific approach with fluorescence resonance energy transfer hybridization probes, TaqMan probes, and molecular beacons and also by non-sequence-specific formats using SYBR gI (<link linkend="ch0065s000000li0091">91</link>). For specificity reasons, most laboratories use sequence-specific formats, and duplex or triplex PCRs for clinically relevant <emphasis>Bordetella</emphasis> species have been developed. Multiplex PCRs for the detection of various respiratory agents, including <emphasis>Bordetella</emphasis> species, are also available but are mostly based on IS<emphasis>481</emphasis> as the sole target (<link linkend="ch0065s000000li0055">55</link>). External quality control programs have been implemented in the United States and European countries (<link linkend="ch0065s000000li0094">94</link>, <link linkend="ch0065s000000li0102">102</link>). Apart from contamination problems in laboratories, pseudo-outbreaks of pertussis have also been reported due to swabs contaminated with <emphasis>Bordetella</emphasis>-DNA from clinic environmental surfaces and from vaccines (<link linkend="ch0065s000000li0103">103</link>).</para>
    </sect1>
    <sect1 id="ch0065s0014">
      <title>Direct Fluorescent-Antibody Staining</title>
      <anchor id="ch0065s000014a0001"/>
      <anchor id="ch0065s000000a0033"/>
      <para id="ch0065s000000p0027">Direct fluorescent-antibody staining (DFA) on NP swabs or aspirates to detect<emphasis>B. pertussis</emphasis> or <emphasis>B. parapertussis</emphasis> is rapid and simple but lacks adequate sensitivity and specificity; for this reason, DFA is not recommended (<link linkend="ch0065s000000li0002">2</link>). DFA methods have largely been supplanted by nucleic acid amplification techniques, which offer greater sensitivity and specificity. Other stains have no role in pertussis diagnosis.</para>
      <sect2 id="ch0065s0014s0001">
        <title>ISOLATION PROCEDURES</title>
        <anchor id="ch0065s000014a0002"/>
        <anchor id="ch0065s000000a0034"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0015">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000015a0001"/>
      <anchor id="ch0065s000000a0035"/>
      <para id="ch0065s000000p0028">Although culture is thought to be almost 100% specific, PCR has mostly replaced it in routine diagnosis (<link linkend="ch0065s000000li0091">91</link>). Detailed information on culture procedures is contained in previous editions of this <emphasis>Manual</emphasis> (<link linkend="ch0065s000000li0104">104</link>). In brief, various culture media, such as RL medium, Bordet-Gengou medium, and Stainer-Scholte medium, can be used for culturing <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis.</emphasis> Most media are supplemented with cephalexin to suppress concomitant bacterial growth. Cultures should be incubated for at least 1 week at 35 to 37°C in ambient atmosphere. The sensitivity of culture depends on the patients’ symptom duration, age, and vaccination status, with a range from &lt;1% in adolescents and adults with more than 3 weeks of coughing to ~60% in young unvaccinated infants with a few days’ duration of symptoms (<link linkend="ch0065s000000li0104">104</link>).</para>
    </sect1>
    <sect1 id="ch0065s0016">
      <title>Other Bordetella species, Achromobacter, Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000016a0001"/>
      <anchor id="ch0065s000000a0036"/>
      <para id="ch0065s000000p0029"><emphasis>Bordetella</emphasis> species other than <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> from clinical material are encountered as Gram-negative nonfermentative bacilli in the laboratory. Information about their growth characteristics and some biochemical reactions that may be used can be found in <anchor id="ch0065s000000a0037"/><link linkend="ch0065s000000a0041">Table 4</link>.</para>
      <para id="ch0065s000000p0030"><emphasis>Achromobacter</emphasis> species can be isolated from clinical samples by the use of simple media and a selective enteric medium such as MacConkey agar. It has been reported that a minority of <emphasis>A. xylosoxidans</emphasis> isolates grow on <emphasis>Burkholderia cepacia</emphasis> selective oxidative-fermentative-polymyxin B-bacitracin-lactose agar or <emphasis>Pseudomonas cepacia</emphasis> agar (30% and 20%, respectively) but do not grow on <emphasis>B. cepacia</emphasis> selective agar (<link linkend="ch0065s000000li0105">105</link>). However, data from the U.S. Cystic Fibrosis Foundation <emphasis>B. cepacia</emphasis> Research Laboratory and Repository (J. J. LiPuma, unpublished data) and a previous study (<link linkend="ch0065s000000li0106">106</link>) indicate that the majority of <emphasis>A. xylosoxidans</emphasis> strains (~60%) grow on <emphasis>B. cepacia</emphasis> selective agar.</para>
      <sect2 id="ch0065s0016s0001">
        <title>IDENTIFICATION</title>
        <anchor id="ch0065s000016a0002"/>
        <anchor id="ch0065s000000a0038"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0017">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000017a0001"/>
      <anchor id="ch0065s000000a0039"/>
      <para id="ch0065s000000p0031">In culture,<emphasis>B. pertussis</emphasis> colonies become visible after 3 to 7 days of incubation, while <emphasis>B. parapertussis</emphasis> colonies are visible after 2 to 3 days. On RL medium, colonies are very small, round, and domed and appear silvery. <emphasis>B. parapertussis</emphasis> colonies are larger and less shiny. The minute colonies on Bordet-Gengou medium have a small zone of beta-hemolysis. <emphasis>B. pertussis</emphasis> is a small coccoid Gram-negative rod which is catalase and oxidase positive (<emphasis>B. parapertussis</emphasis> is oxidase negative). Their identity in pure culture can best be confirmed by agglutination with specific antibodies (<ulink url="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/861059/ID_5_di+.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/861059/ID_5_di+.pdf</ulink>). Basic biochemical characteristics are given in <link linkend="ch0065s000000a0041">Table 4</link>. Due to the fastidious growth of <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis>, commercial systems for Gram-negative rods do not reliably identify both species. For identification, 16S rRNA gene PCR/sequencing may also be employed (<link linkend="ch0065s000000li0107">107</link>). Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) is now used in many hospital clinical laboratories to identify a range of bacterial pathogens. While several <emphasis>Bordetella</emphasis> species are included in databases of FDA-cleared MALDI-TOF MS platforms (e.g., <emphasis>B. pertussis, B. bronchiseptica</emphasis>, and <emphasis>B. parapertussis</emphasis>) not all species are present, and studies on the applicability of MALDI-TOF MS for the identification of <emphasis>Bordetella</emphasis> species are scarce. A recent study suggests that MALDI-TOF MS can be used to distinguish <emphasis>B. pertussis, B. parapertussis</emphasis>, and <emphasis>B. bronchiseptica</emphasis> (<link linkend="ch0065s000000li0080">80</link>, <link linkend="ch0065s000000li0108">108</link>), but more data are required before this identification approach can be recommended for routine identification.</para>
      <anchor id="ch0065s000000a0040"/>
      <beginpage pagenum="950"/>
      <table id="ch0065s000000t0004"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0065s000000a0041"/><link linkend="ch0065s000000a0037">TABLE 4</link></phrase></emphasis> Useful characteristics for differentiating clinically relevant <emphasis>Bordetella</emphasis> species<superscript><emphasis><anchor id="ch0065s000000a0042"/><link linkend="ch0065s000000a0044">a</link></emphasis></superscript>
</title>
        
        <tgroup cols="11">
          <tbody>
            <row>
              <entry><phrase role="center">Test</phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. pertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. parapertussis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. bronchiseptica</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. avium</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">“<emphasis>B. ansorpii</emphasis>”</phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. hinzii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. holmesii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. petrii</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">
                  <emphasis>B. trematum</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="center">Others<superscript><emphasis><anchor id="ch0065s000000a0043"/><link linkend="ch0065s000000a0045">b</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Growth on:</phrase>
              </entry>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
            </row>
            <row>
              <entry><phrase role="left">RL medium</phrase>
              </entry>
              <entry><phrase role="left">+ (3–4 days)</phrase>
              </entry>
              <entry><phrase role="left">+ (2–3 days)</phrase>
              </entry>
              <entry><phrase role="left">+ (1–2 days)</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Columbia agar</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">V</phrase>
              </entry>
              <entry><phrase role="left">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">MacConkey agar</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">(+)</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">ND</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Oxidase</phrase>
              </entry>
              <entry><phrase role="left">+</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Motility</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">V</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Pigment</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="left">Brown</phrase>
              </entry>
              <entry><phrase role="left">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
              <entry><phrase role="left">Yellow</phrase>
              </entry>
              <entry><phrase role="center">Yellow</phrase>
              </entry>
              <entry><phrase role="center">−</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0065s000000a0044"/><link linkend="ch0065s000000a0042">a</link></emphasis></superscript>Symbols and abbreviations: +, ≥90% of the strains are positive; −, ≤10% of the strains are positive; (+), variable growth; V, 10 to 89% of the strains are positive; ND, not determined.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0065s000000a0045"/><link linkend="ch0065s000000a0043">b</link></emphasis></superscript>Others comprise <emphasis>B. bronchialis, B. flabilis, B. sputigena</emphasis>, and <emphasis>B. pseudohinzii.</emphasis></para>
      <para id="ch0065s000000p0032">Isolates of<emphasis>B. pertussis</emphasis> and, happens less often, those of <emphasis>B. parapertussis</emphasis> can undergo a phase change (<link linkend="ch0065s000000li0109">109</link>), and if strains have to be stored, storage should be done from primary cultures; these should be frozen in glycerol at −70°C or in a sucrose/bovine serum albumin medium.</para>
    </sect1>
    <sect1 id="ch0065s0018">
      <title>Other Bordetellae</title>
      <anchor id="ch0065s000018a0001"/>
      <anchor id="ch0065s000000a0046"/>
      <para id="ch0065s000000p0033">Colony morphology is not discriminative for other bordetellae, and the bacteria are small coccoid rods that are catalase positive. In most instances, a biochemical system for identification of Gram-negative bacilli is used, such as API20-NE, Vitek (BioMérieux, Marcy-l’Etoile, France), MicroScan (Siemens, Eschborn, Germany), Phoenix (Becton Dickinson, Franklin Lakes, NJ) (<link linkend="ch0065s000000li0110">110</link>), or others. These systems were validated for nonfermentative rods, among which a few <emphasis>Bordetella</emphasis> species were evaluated. Overall, the specificity of these biochemical systems for these bacteria is not very high, and for the API20 NE and Vitek II systems, it has been proposed that 16S rRNA gene PCR/sequencing be performed if the results of the biochemical identification are not reported as “excellent” or “very good” (<link linkend="ch0065s000000li0110">110</link>). 16S rRNA gene PCR/sequencing and ribotyping, as well as MALDI-TOF MS, offer more reliable identification results, and these tests are available in hospital clinical and reference laboratories (<link linkend="ch0065s000000li0080">80</link>, <link linkend="ch0065s000000li0111">111</link>–<link linkend="ch0065s000000li0113">113</link>). Apart from <emphasis>B. bronchiseptica</emphasis>, the isolation of other bordetellae from clinical samples is a rare event, and their identification should be confirmed by a reference laboratory to avoid misidentification (<link linkend="ch0065s000000li0114">114</link>).</para>
    </sect1>
    <sect1 id="ch0065s0019">
      <title>Achromobacter</title>
      <anchor id="ch0065s000019a0001"/>
      <anchor id="ch0065s000000a0047"/>
      <para id="ch0065s000000p0034"><emphasis>Achromobacter</emphasis> species typically show very limited action on carbohydrates (<link linkend="ch0065s000000li0009">9</link>–<link linkend="ch0065s000000li0012">12</link>), which hampers the accurate identification at the genus level based on biochemical characteristics, and 16S rRNA gene sequence analysis is recommended for this purpose. Likewise, the increased taxonomic diversity and considerable intraspecies diversity observed in this genus make species-level differentiation based on phenotypic characteristics virtually impossible. A PCR assay (based on the 16S rRNA gene) was developed for <emphasis>A. xylosoxidans</emphasis>, but positive results may also be obtained with strains of other <emphasis>Achromobacter</emphasis> species as well as with some <emphasis>Bordetella</emphasis> species (<link linkend="ch0065s000000li0115">115</link>). MALDI-TOF MS has been used successfully to identify <emphasis>A. xylosoxidans</emphasis> (<link linkend="ch0065s000000li0080">80</link>, <link linkend="ch0065s000000li0116">116</link>) and reportedly allows the separation of <emphasis>A. xylosoxidans, A. ruhlandii, A. insolitus</emphasis>, and <emphasis>A. spanius</emphasis> (<link linkend="ch0065s000000li0117">117</link>), although in other studies, species-level identification of <emphasis>Achromobacter</emphasis> spp. with MALDI-TOF MS turned out to be not straightforward (<link linkend="ch0065s000000li0118">118</link>, <link linkend="ch0065s000000li0119">119</link>). In addition, Desai et al. (<link linkend="ch0065s000000li0120">120</link>) noted that strains identified as <emphasis>A. xylosoxidans</emphasis> by phenotypic tests were commonly identified as <emphasis>A. ruhlandii</emphasis> by MALDI-TOF MS. It should be noted that many of the studies referenced above were published prior to the description of additional diversity within the genus <emphasis>Achromobacter and with older versions of databases.</emphasis> More recent work showed that MALDI-TOF MS distinguishes all <emphasis>Achromobacter</emphasis> species (<link linkend="ch0065s000000li0121">121</link>) and can even distinguish between epidemic clones of <emphasis>A. xylosoxidans</emphasis> and <emphasis>A. ruhlandii</emphasis> (<link linkend="ch0065s000000li0122">122</link>). Nevertheless, accuracy of identification based on the default (commercially available) MALDI-TOF MS databases is sometimes low (<link linkend="ch0065s000000li0122">122</link>).</para>
      <para id="ch0065s000000p0035">All established<emphasis>Achromobacter</emphasis> species can be separated using concatenated <emphasis>nusA, eno, rpoB, gltB, lepA, nuoL</emphasis>, and <emphasis>nrdA</emphasis> sequences (<link linkend="ch0065s000000li0010">10</link>, <link linkend="ch0065s000000li0011">11</link>, <link linkend="ch0065s000000li0015">15</link>), and many studies have confirmed that most species can be distinguished based on sequence analysis of the <emphasis>nrdA</emphasis> gene alone (<link linkend="ch0065s000000li0012">12</link>, <link linkend="ch0065s000000li0062">62</link>, <link linkend="ch0065s000000li0085">85</link>, <link linkend="ch0065s000000li0086">86</link>, <link linkend="ch0065s000000li0123">123</link>).</para>
    </sect1>
    <sect1 id="ch0065s0020">
      <title>Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000020a0001"/>
      <anchor id="ch0065s000000a0048"/>
      <para id="ch0065s000000p0036">For<emphasis>Alcaligenes, Advenella, Kerstersia</emphasis>, and <emphasis>Paenalcaligenes</emphasis>, 16S rRNA gene sequence analysis is recommended for accurate identification at the genus level. Members of the genus <emphasis>Advenella</emphasis> can be separated from related species by their inability to assimilate phenyl acetate. <emphasis>Kerstersia</emphasis> strains are oxidase negative. <emphasis>K. gyiorum</emphasis> and <emphasis>K. similis</emphasis> can be distinguished based on the oxidation of <phrase role="small">D</phrase>-galacturonic acid and <phrase role="small">D</phrase>-glucuronic acid (positive in <emphasis>K. gyiorum</emphasis>, negative in <emphasis>K. similis</emphasis>) and <phrase role="small">D</phrase>-serine (negative in <emphasis>K. gyiorum</emphasis>, positive in <emphasis>K. similis</emphasis>). A distinguishing characteristic of <emphasis>A. faecalis</emphasis> isolates is that they reduce nitrite but not nitrate. <emphasis>P. hominis</emphasis> cannot assimilate citrate.</para>
      <sect2 id="ch0065s0020s0001">
        <title>TYPING SYSTEMS</title>
        <anchor id="ch0065s000020a0002"/>
        <anchor id="ch0065s000000a0049"/>
        <para id="ch0065s000000p0037"><emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> show limited genomic heterogeneity (<link linkend="ch0065s000000li0037">37</link>), but some polymorphic regions, such as the toxin gene (<emphasis>ptx</emphasis>), the toxin promoter (<emphasis>ptxP</emphasis>), the pertactin gene (<emphasis>prn</emphasis>), and others, have undergone changes whose cause is not totally clear (<link linkend="ch0065s000000li0124">124</link>, <link linkend="ch0065s000000li0125">125</link>). Expression of fimbriae undergoes temporal changes, possibly influenced by vaccine coverage (<link linkend="ch0065s000000li0125">125</link>). Nucleic acids of circulating isolates of <emphasis>B. pertussis</emphasis> have been typed by an array of methods, such as conventional and next-generation sequencing (<link linkend="ch0065s000000li0029">29</link>, <link linkend="ch0065s000000li0125">125</link>), pulsed-field gel electrophoresis, variable number of tandem repeat analysis or multilocus variable-number tandem repeat analysis (<link linkend="ch0065s000000li0126">126</link>, <link linkend="ch0065s000000li0127">127</link>), restriction fragment length polymorphism (<link linkend="ch0065s000000li0091">91</link>), single nucleotide polymorphism (SNP) typing (<link linkend="ch0065s000000li0128">128</link>), real-time PCR (<link linkend="ch0065s000000li0129">129</link>), and others (<link linkend="ch0065s000000li0111">111</link>). Other methods use the proteome as a distinguishing parameter (<link linkend="ch0065s000000li0115">115</link>). Depending on the problem in question, different typing methods may be employed, and the results can mostly not be compared directly. Conventional multilocus sequence typing (MLST) approaches show low discriminatory power, but a recently developed whole-genome MLST (wgMLST) scheme yielded results in concordance with whole-genome SNP typing and allowed accurate resolution of outbreak and sporadic cases (<link linkend="ch0065s000000li0130">130</link>). Similar typing methods have been used for isolates of <emphasis>B. holmesii</emphasis> (<link linkend="ch0065s000000li0024">24</link>).</para>
        <para id="ch0065s000000p0038">Typing of<emphasis>A. xylosoxidans</emphasis> isolates with pulsed-field gel electrophoresis of fragments obtained after digestion with XbaI, SpeI, or DraI has been used in several studies (<link linkend="ch0065s000000li0060">60</link>, <link linkend="ch0065s000000li0063">63</link>, <link linkend="ch0065s000000li0131">131</link>) and is reported to have high discriminatory power; data from a recent study suggest that the discriminatory power of pulsed-field gel electrophoresis is higher than that of MLST (<link linkend="ch0065s000000li0062">62</link>). Randomly amplified polymorphic DNA PCR (<link linkend="ch0065s000000li0058">58</link>) and PCR with enterobacterial repetitive intergenic consensus or repetitive extragenic palindromic primers (<link linkend="ch0065s000000li0061">61</link>) have also been used. Two MLST schemes can be used to type all named <emphasis>Achromobacter</emphasis> species (<link linkend="ch0065s000000li0015">15</link>, <link linkend="ch0065s000000li0132">132</link>).</para>
        <anchor id="ch0065s000000a0050"/>
        <beginpage pagenum="951"/>
      </sect2>
      <sect2 id="ch0065s0020s0002">
        <title>SEROLOGIC TESTS</title>
        <anchor id="ch0065s000020a0003"/>
        <anchor id="ch0065s000000a0051"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0021">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000021a0001"/>
      <anchor id="ch0065s000000a0052"/>
      <para id="ch0065s000000p0039">Serologic assays for pertussis can be used for diagnostic confirmation and testing of specimens in the context of a suspected outbreak. When the serologic test is used at a single point in time, specimen collection is optimally performed 2 to 8 weeks after cough onset, when antibodies to<emphasis>B. pertussis</emphasis> are expected to be highest. Specimens may also be collected up to 12 weeks after cough onset (<link linkend="ch0065s000000li0133">133</link>) (<ulink url="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt10-pertussis.html">https://www.cdc.gov/vaccines/pubs/surv-manual/chpt10-pertussis.html</ulink>). Enzyme-linked immunosorbent assays or bead-based assays to quantify anti-PT antibody levels are recommended diagnostic techniques (<link linkend="ch0065s000000li0134">134</link>–<link linkend="ch0065s000000li0136">136</link>) that can be performed with paired (acute- and convalescent-phase) or single serum samples. Paired-sample serology is the optimal method of serologic diagnosis (<link linkend="ch0065s000000li0137">137</link>), but single sample serology also provides good sensitivity and specificity to determine cases in older children, adolescents, and adults (<link linkend="ch0065s000000li0134">134</link>, <link linkend="ch0065s000000li0138">138</link>, <link linkend="ch0065s000000li0139">139</link>). A WHO reference preparation for human pertussis serology is available (<link linkend="ch0065s000000li0140">140</link>), and quantitative results in pertussis serology should be reported in international units per milliliter. For single-sample serology, IgG anti-PT antibodies below 40 IU/ml are not indicative of recent contact, whereas levels above 100 IU/ml can be used as an indicator of recent contact with the bacteria (<link linkend="ch0065s000000li0135">135</link>, <link linkend="ch0065s000000li0141">141</link>–<link linkend="ch0065s000000li0143">143</link>). Anti-PT IgG antibodies are primarily measured, and anti-PT IgA may serve as an additional test for equivocal results (&gt;40 IU/ml and &lt;100 IU/ml). The measurement of IgM antibodies as well as other methods, such as immunoblotting, complement fixation, agglutination, and others, are not recommended (<link linkend="ch0065s000000li0135">135</link>). Serology is unable to detect infection with <emphasis>B. parapertussis</emphasis> and cannot distinguish between vaccine- and infection-induced immunological responses (symptomatic or asymptomatic infection) to <emphasis>B. pertussis</emphasis> (<link linkend="ch0065s000000li0135">135</link>, <link linkend="ch0065s000000li0142">142</link>, <link linkend="ch0065s000000li0144">144</link>). Commercial serological assays vary in their analytic and clinical accuracy and must be calibrated to a reference standard (<link linkend="ch0065s000000li0144">144</link>, <link linkend="ch0065s000000li0145">145</link>). Pertussis serology cannot be reliably interpreted for 1 year after vaccination with acellular vaccines (<link linkend="ch0065s000000li0135">135</link>). External quality control programs for pertussis serology are available (<link linkend="ch0065s000000li0145">145</link>).</para>
      <sect2 id="ch0065s0021s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES</title>
        <anchor id="ch0065s000021a0002"/>
        <anchor id="ch0065s000000a0053"/>
      </sect2>
    </sect1>
    <sect1 id="ch0065s0022">
      <title>B. pertussis and B. parapertussis</title>
      <anchor id="ch0065s000022a0001"/>
      <anchor id="ch0065s000000a0054"/>
      <para id="ch0065s000000p0040"><emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> demonstrate <emphasis>in vitro</emphasis> susceptibility to a range of antibiotics, including some penicillins, macrolides, ketolides, fluoroquinolones, tetracyclines, chloramphenicol, and trimethoprim-sulfamethoxazole, whereas they are resistant to most oral cephalosporins (<link linkend="ch0065s000000li0002">2</link>). Notably, in China, there is evidence of macrolide resistance (mediated by a mutation in the macrolide binding domain of the 23S rRNA gene) among <emphasis>B. pertussis</emphasis> strains (<link linkend="ch0065s000000li0146">146</link>–<link linkend="ch0065s000000li0149">149</link>) and this resistance has been reported in other countries as well (<link linkend="ch0065s000000li0150">150</link>, <link linkend="ch0065s000000li0151">151</link>). In contrast to other bacterial diseases, the exact relationship between the pharmacokinetics and pharmacodynamics of these antibiotics and bordetella <emphasis>in vitro</emphasis> susceptibility is unknown. Furthermore, the effect of antibiotic treatment on the severity or duration of pertussis symptoms is not well documented (<link linkend="ch0065s000000li0043">43</link>, <link linkend="ch0065s000000li0152">152</link>).</para>
      <para id="ch0065s000000p0041">Current methods for antibiotic susceptibility testing of<emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> are not standardized. If testing is done, the methods include macro- and microbroth dilution, agar dilution methods, breakpoint methods, and the Etest, whereas the disk diffusion method is mostly not feasible (<link linkend="ch0065s000000li0043">43</link>). Erythromycin resistance may be evaluated by the disk diffusion method, using RL (charcoal agar supplemented with defibrinated horse blood) medium without antibiotics and employing a 15-μg erythromycin disk. Routine antibiotic susceptibility testing of <emphasis>B. pertussis</emphasis> isolates is not recommended and should be done only when special clinical or epidemiological circumstances are encountered (<link linkend="ch0065s000000li0043">43</link>). Continued surveillance of <emphasis>B. pertussis</emphasis> isolates should also include antimicrobial susceptibility testing.</para>
    </sect1>
    <sect1 id="ch0065s0023">
      <title>Other Bordetellae</title>
      <anchor id="ch0065s000023a0001"/>
      <anchor id="ch0065s000000a0055"/>
      <para id="ch0065s000000p0042"><emphasis>B. bronchiseptica</emphasis> possesses a β-lactamase (<link linkend="ch0065s000000li0153">153</link>) and is resistant to many penicillins and cephalosporins and mostly resistant to trimethoprim-sulfamethoxazole (<link linkend="ch0065s000000li0154">154</link>). A study of canine and feline isolates (<link linkend="ch0065s000000li0155">155</link>) showed that most isolates are susceptible to amoxicillin-clavulanic acid, tetracycline, gentamicin, and one fluoroquinolone class compound. <emphasis>B. avium</emphasis> was resistant to cefuroxime, trimethoprim-sulfamethoxazole, and tetracycline and susceptible to ampicillin, mezlocillin, and gentamicin (<link linkend="ch0065s000000li0154">154</link>). Antimicrobial susceptibility testing of other bordetella isolates should be reported in accordance with the reporting for other infrequently isolated and fastidious nonfermentative Gram-negative rods. In these cases, <emphasis>in vitro</emphasis> resistance does not necessarily reflect clinical ineffectiveness.</para>
    </sect1>
    <sect1 id="ch0065s0024">
      <title>Achromobacter</title>
      <anchor id="ch0065s000024a0001"/>
      <anchor id="ch0065s000000a0056"/>
      <para id="ch0065s000000p0043">Resistance is frequently observed in<emphasis>Achromobacter</emphasis> isolates (<link linkend="ch0065s000000li0156">156</link>–<link linkend="ch0065s000000li0161">161</link>), and <emphasis>A. xylosoxidans</emphasis> isolates are typically susceptible only to imipenem, piperacillin, ticarcillin-clavulanic acid, ceftazidime, and trimethoprim-sulfamethoxazole (<link linkend="ch0065s000000li0156">156</link>, <link linkend="ch0065s000000li0159">159</link>). Aminoglycosides, extended-spectrum cephalosporins other than ceftazidime, and quinolones show no activity (<link linkend="ch0065s000000li0156">156</link>). The majority of the strains are resistant to conventional tobramycin concentrations, but 41% of the strains are inhibited by the higher tobramycin concentrations achievable by aerosol delivery of the antibiotic (<link linkend="ch0065s000000li0156">156</link>). Similarly, 92% of strains are inhibited by high doses of colistin (100 or 200 μg/ml) (<link linkend="ch0065s000000li0157">157</link>). The most active combinations of antibiotics include chloramphenicol-minocycline, ciprofloxacin-imipenem, and ciprofloxacin-meropenem (<link linkend="ch0065s000000li0157">157</link>), as well as combinations with trimethoprim-sulfamethoxazole or tobramycin (<link linkend="ch0065s000000li0160">160</link>). <emphasis>A. xylosoxidans</emphasis> is resistant to azithromycin and clarithromycin, and only modest synergistic and/or additive activities were observed when azithromycin was combined with meropenem or trimethoprim-sulfamethoxazole (<link linkend="ch0065s000000li0158">158</link>). These data correlate well with many smaller clinical studies and case reports.</para>
      <para id="ch0065s000000p0044">Antimicrobial susceptibility data for other<emphasis>Achromobacter</emphasis> species are rare, but <emphasis>A. spanius</emphasis> and <emphasis>A. insolitus</emphasis> are resistant to most fluoroquinolones, macrolides, and cephalosporins tested (<link linkend="ch0065s000000li0009">9</link>), while a blood isolate of <emphasis>A. piechaudii</emphasis> is resistant to ampicillin, cefpodoxime, and gentamicin but susceptible to all other antibiotics tested (<link linkend="ch0065s000000li0162">162</link>). More than 90% of <emphasis>Achromobacter</emphasis> species isolates recovered from Danish CF patients are resistant to amikacin, ciprofloxacin, and tobramycin, and particularly high MICs were recorded for aztreonam (&gt;256 μg/ml) and fosfomycin (&gt;1,024 μg/ml) (<link linkend="ch0065s000000li0163">163</link>). The lowest MICs were observed for meropenem (94% of isolates were susceptible), piperacillin-tazobactam (all isolates were susceptible), and trimethoprim-sulfamethoxazole. Colistin (MIC<subscript>90</subscript> = 8 μg/ml) and ceftazidime (MIC<subscript>90</subscript> = 24 μg/ml), two antibiotics commonly used for inhalation therapy, exhibited good activity (<link linkend="ch0065s000000li0163">163</link>). In a recent study, no meaningful differences in MIC were found between <emphasis>A. xylosoxidans</emphasis> and <emphasis>A. insuavis</emphasis> strains (<link linkend="ch0065s000000li0161">161</link>). Like many other bacteria, <emphasis>Achromobacter</emphasis> species readily form biofilms <emphasis>in vitro</emphasis>, and biofilm-grown cells showed markedly reduced susceptibility to many antibiotics, with biofilm-inhibitory concentrations higher than the achievable aerosolized concentrations (<link linkend="ch0065s000000li0164">164</link>, <link linkend="ch0065s000000li0165">165</link>). Nevertheless, several strains showed MICs and biofilm-inhibitory concentrations that were below the achievable aerosolized concentrations for levofloxacin and tobramycin (<link linkend="ch0065s000000li0165">165</link>).</para>
      <anchor id="ch0065s000000a0057"/>
      <beginpage pagenum="952"/>
    </sect1>
    <sect1 id="ch0065s0025">
      <title>Alcaligenes, Kerstersia, Advenella, and Paenalcaligenes</title>
      <anchor id="ch0065s000025a0001"/>
      <anchor id="ch0065s000000a0058"/>
      <para id="ch0065s000000p0045"><emphasis>A. faecalis</emphasis> is more susceptible to antibiotics than <emphasis>A. xylosoxidans.</emphasis> Most <emphasis>A. faecalis</emphasis> strains are resistant to amoxicillin, ticarcillin, aztreonam, kanamycin, gentamicin, and nalidixic acid, while they are susceptible to the combination of amoxicillin or ticarcillin with clavulanic acid, to various cephalosporins, and to ciprofloxacin (<link linkend="ch0065s000000li0166">166</link>). Most <emphasis>Kerstersia</emphasis> isolates are susceptible to ciprofloxacin and cefotaxime (<link linkend="ch0065s000000li0008">8</link>), although two more recently described isolates are ciprofloxacin resistant (<link linkend="ch0065s000000li0167">167</link>). Recent clinical isolates were found to be susceptible to cefepime, gentamicin, and trimethoprim-sulfamethoxazole (<link linkend="ch0065s000000li0167">167</link>, <link linkend="ch0065s000000li0168">168</link>), and a recent <emphasis>K. gyiorum</emphasis> leg wound infection was successfully treated with meropenem (<link linkend="ch0065s000000li0073">73</link>). Antimicrobial susceptibility in <emphasis>Advenella</emphasis> and <emphasis>Paenalcaligenes</emphasis> species has not yet been studied.</para>
      <sect2 id="ch0065s0025s0001">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0065s000025a0002"/>
        <anchor id="ch0065s000000a0059"/>
        <para id="ch0065s000000p0046">The usefulness of diagnostic methods in pertussis and parapertussis cases is dependent on the duration of symptoms (<anchor id="ch0065s000000a0060"/><link linkend="ch0065s000000a0061">Fig. 1</link>). Due to their sensitivity and speed, nucleic acid amplification tests are the preferred method for the direct detection of <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> (<link linkend="ch0065s000000li0169">169</link>). Suggestions for the interpretation and reporting of real-time PCR results are given in <link linkend="ch0065s000000a0020">Table 3</link>.</para>
        <para id="ch0065s000000p0047">If culture is performed, isolation of<emphasis>B. pertussis</emphasis> or <emphasis>B. parapertussis</emphasis> suggests infection, although the sensitivity is sufficiently high only in neonates and unvaccinated infants. Routine antimicrobial susceptibility testing of isolates is not necessary. Culture remains necessary for surveillance of circulating <emphasis>B. pertussis</emphasis> and <emphasis>B. parapertussis</emphasis> isolates but is not typically performed in clinical laboratories.</para>
        <para id="ch0065s000000p0048">Serological diagnosis of pertussis is usually based on single-sample serology collected 2 to 8 weeks following the onset of cough symptoms. Results cannot be correctly interpreted for about 1 year after vaccination with acellular pertussis vaccines. IgG anti-PT levels of ≥100 IU/ml are indicative of recent contact. In adolescent and adult populations, IgG anti-PT levels of &lt;40 IU/ml may be interpreted as not indicative of recent infection (<link linkend="ch0065s000000li0135">135</link>). Except in Massachusetts, serology is not accepted as a confirmation of cases in the United States. Many European countries with statutory notification and laboratory confirmation accept serology as proof of infection.</para>
        <para id="ch0065s000000p0049">Similar to other rarely isolated Gram-negative nonenteric rods, the clinical relevance of species belonging to the genera<emphasis>Achromobacter, Alcaligenes, Kerstersia, Advenella</emphasis>, and <emphasis>Paenalcaligenes</emphasis> from clinical material should be discussed on a case-by-case basis between the microbiology laboratory and the clinician. Antimicrobial testing of these species should be performed and can be helpful in guiding therapeutic decisions.</para>
        <figure id="ch0065s000000f0001"><title><phrase role="figureLabel"><anchor id="ch0065s000000a0061"/><link linkend="ch0065s000000a0060">FIGURE 1</link></phrase> Schematic graph of findings and diagnostic procedures in pertussis. (Courtesy of Nicole Guiso, Institut Pasteur, Paris, France.)</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0065f01.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0065s0025s0002">
        <title>REFERENCES</title>
        <anchor id="ch0065s000025a0003"/>
        <anchor id="ch0065s000000a0062"/>
        <anchor id="ch0065s000000a0063"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0065s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Busse HJ, Stolz A.</emphasis> 2006. <citetitle><emphasis>Achromobacter</emphasis></citetitle>, <citetitle><emphasis>Alcaligenes</emphasis></citetitle> and related genera, p 675–700. <citetitle><emphasis>In</emphasis></citetitle> Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E (ed), <citetitle><emphasis>The Prokaryotes</emphasis></citetitle>, vol 5. Springer, Heidelberg, Germany.</para>
          </listitem>
          <listitem id="ch0065s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Mattoo S, Cherry JD.</emphasis> 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> and other <citetitle><emphasis>Bordetella</emphasis></citetitle> subspecies. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">18:</emphasis>326–382.</para>
          </listitem>
          <listitem id="ch0065s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Vandamme P, Heyndrickx M, Vancanneyt M, Hoste B, De Vos P, Falsen E, Kersters K, Hinz KH.</emphasis> 1996. <citetitle><emphasis>Bordetella</emphasis></citetitle> trematum sp. nov., isolated from wounds and ear infections in humans, and reassessment of <citetitle><emphasis>Alcaligenes denitrificans</emphasis></citetitle> Rüger and Tan 1983. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>849–858.</para>
          </listitem>
          <listitem id="ch0065s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Vandamme P, Hommez J, Vancanneyt M, Monsieurs M, Hoste B, Cookson B, Wirsing von König CH, Kersters K, Blackall PJ.</emphasis> 1995. <citetitle><emphasis>Bordetella</emphasis></citetitle> hinzii sp. nov., isolated from poultry and humans. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>37–45.</para>
          </listitem>
          <listitem id="ch0065s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Weyant RS, Hollis DG, Weaver RE, Amin MF, Steigerwalt AG, O’Connor SP, Whitney AM, Daneshvar MI, Moss CW, Brenner DJ.</emphasis> 1995. <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> sp. nov., a new gram-negative species associated with septicemia. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1–7.</para>
          </listitem>
          <listitem id="ch0065s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Vandamme PA, Peeters C, Cnockaert M, Inganas E, Falsen E, Moore ER, Nunes OC, Manaia CM, Spilker T, LiPuma JJ.</emphasis> 2015. <citetitle><emphasis>Bordetella bronchialis</emphasis></citetitle> sp. nov., <citetitle><emphasis>Bordetella flabilis</emphasis></citetitle> sp. nov. and <citetitle><emphasis>Bordetella sputigena</emphasis></citetitle> sp. nov., isolated from human respiratory specimens, and reclassification of <citetitle><emphasis>Achromobacter sediminum</emphasis></citetitle> Zhang et al. 2014 as <citetitle><emphasis>Verticia sediminum</emphasis></citetitle> gen. nov., comb. nov. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> 65<emphasis role="strong">:</emphasis>3674–3682.</para>
          </listitem>
          <listitem id="ch0065s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, et al.</emphasis> 2003. Comparative analysis of the genome sequences of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle>, <citetitle><emphasis>Bordetella parapertussis</emphasis></citetitle> and <citetitle><emphasis>Bordetella bronchiseptica. Nat Genet</emphasis></citetitle> <emphasis role="strong">35:</emphasis>32–40.</para>
          </listitem>
          <listitem id="ch0065s000000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Coenye T, Vancanneyt M, Cnockaert MC, Falsen E, Swings J, Vandamme P.</emphasis> 2003. <citetitle><emphasis>Kerstersia gyiorum</emphasis></citetitle> gen. nov., sp. nov., a novel <citetitle><emphasis>Alcaligenes faecalis</emphasis></citetitle>-like organism isolated from human clinical samples, and reclassification of <citetitle><emphasis>Alcaligenes denitrificans</emphasis></citetitle> Rüger and Tan 1983 as <citetitle><emphasis>Achromobacter denitrificans</emphasis></citetitle> comb. nov. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1825–1831.</para>
          </listitem>
          <listitem id="ch0065s000000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Coenye T, Vancanneyt M, Falsen E, Swings J, Vandamme P.</emphasis> 2003. <citetitle><emphasis>Achromobacter insolitus</emphasis></citetitle> sp. nov. and <citetitle><emphasis>Achromobacter spanius</emphasis></citetitle> sp. nov., from human clinical samples. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1819–1824.</para>
          </listitem>
          <listitem id="ch0065s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Vandamme P, Moore ER, Cnockaert M, De Brandt E, Svensson-Stadler L, Houf K, Spilker T, Lipuma JJ.</emphasis> 2013. <citetitle><emphasis>Achromobacter animicus</emphasis></citetitle> sp. nov., <citetitle><emphasis>Achromobacter mucicolens</emphasis></citetitle> sp. nov., <citetitle><emphasis>Achromobacter pulmonis</emphasis></citetitle> sp. nov. and <citetitle><emphasis>Achromobacter spiritinus</emphasis></citetitle> sp. nov., from human clinical samples. <citetitle><emphasis>Syst Appl Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1–10.</para>
          </listitem>
          <listitem id="ch0065s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Vandamme P, Moore ER, Cnockaert M, Peeters C, Svensson-Stadler L, Houf K, Spilker T, LiPuma JJ.</emphasis> 2013. Classification of <citetitle><emphasis>Achromobacter</emphasis></citetitle> genogroups 2, 5, 7 and 14 as <citetitle><emphasis>Achromobacter insuavis</emphasis></citetitle> sp. nov., <citetitle><emphasis>Achromobacter aegrifaciens</emphasis></citetitle> sp. nov., <citetitle><emphasis>Achromobacter anxifer</emphasis></citetitle> sp. nov. and <citetitle><emphasis>Achromobacter dolens</emphasis></citetitle> sp. nov., respectively. <citetitle><emphasis>Syst Appl Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>474–482.</para>
          </listitem>
          <listitem id="ch0065s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Vandamme PA, Peeters C, Inganas E, Cnockaert M, Houf K, Spilker T, Moore ER, LiPuma JJ.</emphasis> 2016. Taxonomic dissection of <citetitle><emphasis>Achromobacter denitrificans</emphasis></citetitle> Coenye et al. 2003 and proposal of <citetitle><emphasis>Achromobacter agilis</emphasis></citetitle> sp. nov., nom. rev., <citetitle><emphasis>Achromobacter pestifer</emphasis></citetitle> sp. nov., nom. rev., <citetitle><emphasis>Achromobacter kerstersii</emphasis></citetitle> sp. nov. and <citetitle><emphasis>Achromobacter deleyi</emphasis></citetitle> sp. nov. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> 66<emphasis role="strong">:</emphasis>3708–3717.</para>
          </listitem>
          <listitem id="ch0065s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Vandamme PA, Peeters C, Cnockaert M, Gomila M, Moore ER, Spilker T, LiPuma JJ.</emphasis> 2016. Reclassification of <citetitle><emphasis>Achromobacter spiritinus</emphasis></citetitle> Vandamme et al. 2013 as a later heterotypic synonym of <citetitle><emphasis>Achromobacter marplatensis</emphasis></citetitle> Gomila et al. 2011. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1641–1644.</para>
          </listitem>
          <listitem id="ch0065s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Dumolin C, Peeters C, Ehsani E, Tahon G, De Canck E, Cnockaert M, Boon N, Vandamme P.</emphasis> 2020. <citetitle><emphasis>Achromobacter veterisilvae</emphasis></citetitle> sp. nov., from a mixed hydrogen-oxidizing bacteria enrichment reactor for microbial protein production. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>530–536.</para>
          </listitem>
          <listitem id="ch0065s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Spilker T, Vandamme P, Lipuma JJ.</emphasis> 2012. A multilocus sequence typing scheme implies population structure and reveals several putative novel <citetitle><emphasis>Achromobacter</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3010–3015.</para>
          </listitem>
          <listitem id="ch0065s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Coenye T, Vanlaere E, Samyn E, Falsen E, Larsson P, Vandamme P.</emphasis> 2005. <citetitle><emphasis>Advenella incenata</emphasis></citetitle> gen. nov., sp. nov., a novel member of the <citetitle><emphasis>Alcaligenaceae</emphasis></citetitle>, isolated from various clinical samples. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>251–256.</para>
          </listitem>
          <listitem id="ch0065s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Gibello A, Vela AI, Martín M, Barra-Caracciolo A, Grenni P, Fernández-Garayzábal JF.</emphasis> 2009. Reclassification of the members of the genus <citetitle><emphasis>Tetrathiobacter</emphasis></citetitle> Ghosh et al. 2005 to the genus <citetitle><emphasis>Advenella</emphasis></citetitle> Coenye et al. 2005. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1914–1918.</para>
          </listitem>
          <listitem id="ch0065s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Kämpfer P, Falsen E, Langer S, Lodders N, Busse HJ.</emphasis> 2010. <citetitle><emphasis>Paenalcaligenes hominis</emphasis></citetitle> gen. nov., sp. nov., a new member of the family <citetitle><emphasis>Alcaligenaceae. Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1537–1542.</para>
          </listitem>
          <listitem id="ch0065s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Bordet J, Gengou U.</emphasis> 1906. Le microbe de la coqueluche. <citetitle><emphasis>Ann Inst Pasteur (Paris)</emphasis></citetitle> <emphasis role="strong">20:</emphasis>46–68.</para>
          </listitem>
          <listitem id="ch0065s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Sebaihia M, Preston A, Maskell DJ, Kuzmiak H, Connell TD, King ND, Orndorff PE, Miyamoto DM, Thomson NR, Harris D, Goble A, Lord A, Murphy L, Quail MA, Rutter S, Squares R, Squares S, Woodward J, Parkhill J, Temple LM.</emphasis> 2006. Comparison of the genome sequence of the poultry pathogen <citetitle><emphasis>Bordetella avium</emphasis></citetitle> with those of <citetitle><emphasis>B. bronchiseptica</emphasis></citetitle>, <citetitle><emphasis>B. pertussis</emphasis></citetitle>, and <citetitle><emphasis>B. parapertussis</emphasis></citetitle> reveals extensive diversity in surface structures associated with host interaction. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">188:</emphasis>6002–6015.</para>
          </listitem>
          <listitem id="ch0065s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Gross R, Guzman CA, Sebaihia M, dos Santos VA, Pieper DH, Koebnik R, Lechner M, Bartels D, Buhrmester J, Choudhuri JV, Ebensen T, Gaigalat L, Herrmann S, Khachane AN, Larisch C, Link S, Linke B, Meyer F, Mormann S, Nakunst D, Rückert C, Schneiker-Bekel S, Schulze K, Vorhölter FJ, Yevsa T, Engle JT, Goldman WE, Pühler A, Göbel UB, Goesmann A, Blöcker H, Kaiser O, Martinez-Arias R.</emphasis> 2008. The missing link: Bordetella petrii is endowed with both the metabolic versatility of environmental bacteria and virulence traits of pathogenic bordetellae. <citetitle><emphasis>BMC Genomics</emphasis></citetitle> <emphasis role="strong">9:</emphasis>449.</para>
          </listitem>
          <listitem id="ch0065s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Park J, Zhang Y, Buboltz AM, Zhang X, Schuster SC, Ahuja U, Liu M, Miller JF, Sebaihia M, Bentley SD, Parkhill J, Harvill ET.</emphasis> 2012. Comparative genomics of the classical <citetitle><emphasis>Bordetella</emphasis></citetitle> subspecies: the evolution and exchange of virulence-associated diversity amongst closely related pathogens. <citetitle><emphasis>BMC Genomics</emphasis></citetitle> <emphasis role="strong">13:</emphasis>545.</para>
          </listitem>
          <listitem id="ch0065s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Linz B, Ivanov YV, Preston A, Brinkac L, Parkhill J, Kim M, Harris SR, Goodfield LL, Fry NK, Gorringe AR, Nicholson TL, Register KB, Losada L, Harvill ET.</emphasis> 2016. Acquisition and loss of virulence-associated factors during genome evolution and speciation in three clades of <citetitle><emphasis>Bordetella</emphasis></citetitle> species. <citetitle><emphasis>BMC Genomics</emphasis></citetitle> <emphasis role="strong">17:</emphasis>767.</para>
          </listitem>
          <listitem id="ch0065s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Mooi FR, Bruisten S, Linde I, Reubsaet F, Heuvelman K, van der Lee S, King AJ.</emphasis> 2012. Characterization of <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> isolates from patients with pertussis-like illness in The Netherlands. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>289–291.</para>
          </listitem>
          <listitem id="ch0065s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Pittet LF, Emonet S, Schrenzel J, Siegrist CA, Posfay-Barbe KM.</emphasis> 2014. <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle>: an under-recognised <citetitle><emphasis>Bordetella</emphasis></citetitle> species. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>510–519.</para>
          </listitem>
          <listitem id="ch0065s000000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Gerlach G, Janzen S, Beier D, Gross R.</emphasis> 2004. Functional characterization of the BvgAS two-component system of <citetitle><emphasis>Bordetella holmesii. Microbiology (Reading)</emphasis></citetitle> <emphasis role="strong">150:</emphasis>3715–3729.</para>
          </listitem>
          <listitem id="ch0065s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Hewlett EL, Donato GM, Gray MC.</emphasis> 2006. Macrophage cytotoxicity produced by adenylate cyclase toxin from <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle>: more than just making cyclic AMP! <citetitle><emphasis>Mol Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>447–459.</para>
          </listitem>
          <listitem id="ch0065s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Hijnen M, He Q, Schepp R, Van Gageldonk P, Mertsola J, Mooi FR, Berbers GA.</emphasis> 2008. Antibody responses to defined regions of the <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> virulence factor pertactin. <citetitle><emphasis>Scand J Infect Dis</emphasis></citetitle> <emphasis role="strong">40:</emphasis>94–104.</para>
          </listitem>
          <listitem id="ch0065s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Queenan AM, Cassiday PK, Evangelista A.</emphasis> 2013. Pertactin-negative variants of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> in the United States. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">368:</emphasis>583–584.</para>
          </listitem>
          <listitem id="ch0065s000000li0030" role="bibliographyEntry">
            <anchor id="ch0065s000000a0064"/>
            <para>30.<emphasis role="strong">Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, Guiso N.</emphasis> 2012. Evolution of French <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> and <citetitle><emphasis>Bordetella parapertussis</emphasis></citetitle> isolates: increase of bordetellae not expressing pertactin. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>E340–E346.</para>
          </listitem>
          <listitem id="ch0065s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Bodilis H, Guiso N.</emphasis> 2013. Virulence of pertactin-negative <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> isolates from infants, France. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>471–474.</para>
          </listitem>
          <listitem id="ch0065s000000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Kurushima J, Kuwae A, Abe A.</emphasis> 2012. The type III secreted protein BspR regulates the virulence genes in <citetitle><emphasis>Bordetella bronchiseptica. PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e38925.</para>
          </listitem>
          <listitem id="ch0065s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Kuncharoen N, Muramatsu Y, Shibata C, Kamakura Y, Nakagawa Y, Tanasupawat S.</emphasis> 2017. <citetitle><emphasis>Achromobacter aloeverae</emphasis></citetitle> sp. nov., isolated from the root of <citetitle><emphasis>Aloe vera</emphasis></citetitle> (L.) Burm.f. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>37–41.</para>
          </listitem>
          <listitem id="ch0065s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ.</emphasis> 2016. Pertussis: microbiology, disease, treatment, and prevention. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">29:</emphasis>449–486.</para>
          </listitem>
          <listitem id="ch0065s000000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Hitz DA, Tewald F, Eggers M.</emphasis> 2020. Seasonal <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> pattern in the period from 2008 to 2018 in Germany. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>474.</para>
          </listitem>
          <listitem id="ch0065s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Leong RNF, Wood JG, Turner RM, Newall AT.</emphasis> 2019. Estimating seasonal variation in Australian pertussis notifications from 1991 to 2016: evidence of spring to summer peaks. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">147:</emphasis>e155.</para>
          </listitem>
          <listitem id="ch0065s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Brinig MM, Cummings CA, Sanden GN, Stefanelli P, Lawrence A, Relman DA.</emphasis> 2006. Significant gene order and expression differences in <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> despite limited gene content variation. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">188:</emphasis>2375–2382.</para>
          </listitem>
          <listitem id="ch0065s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">von König CH, Halperin S, Riffelmann M, Guiso N.</emphasis> 2002. Pertussis of adults and infants. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">2:</emphasis>744–750.</para>
          </listitem>
          <listitem id="ch0065s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Guiso N.</emphasis> 2009. <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> and pertussis vaccines. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1565–1569.</para>
          </listitem>
          <listitem id="ch0065s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Watanabe M, Connelly B, Weiss AA.</emphasis> 2006. Characterization of serological responses to pertussis. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>341–348.</para>
          </listitem>
          <listitem id="ch0065s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW.</emphasis> 2017. An update of the global burden of pertussis in children younger than 5 years: a modelling study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>974–980.</para>
          </listitem>
          <listitem id="ch0065s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">van der Maas NAT, Hoes J, Sanders EAM, de Melker HE.</emphasis> 2017. Severe underestimation of pertussis related hospitalizations and deaths in the Netherlands: a capture-recapture analysis. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">35:</emphasis>4162–4166.</para>
          </listitem>
          <listitem id="ch0065s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Plotkin S.</emphasis> 2005. Aims, scope and findings of the global pertussis initiative. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">24</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S5–S6.</para>
          </listitem>
          <listitem id="ch0065s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Liko J, Robison SG, Cieslak PR.</emphasis> 2017. Do pertussis vaccines protect against <citetitle><emphasis>Bordetella parapertussis</emphasis></citetitle>? <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1795–1797.</para>
          </listitem>
          <listitem id="ch0065s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Cagney M, McIntyre PB, Heron L, Giammanco A, MacIntyre CR.</emphasis> 2008. The relationship between pertussis symptomatology, incidence and serology in adolescents. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">26:</emphasis>5547–5553.</para>
          </listitem>
          <listitem id="ch0065s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R, Group AS, APERT Study Group.</emphasis> 2006. <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">43:</emphasis>151–157.</para>
          </listitem>
          <listitem id="ch0065s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Kretzschmar M, Teunis PF, Pebody RG.</emphasis> 2010. Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">7</emphasis><emphasis role="strong">:</emphasis>e1000291.</para>
          </listitem>
          <listitem id="ch0065s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Wendelboe AM, Hudgens MG, Poole C, Van Rie A.</emphasis> 2007. Estimating the role of casual contact from the community in transmission of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> to young infants. <citetitle><emphasis>Emerg Themes Epidemiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>15.</para>
          </listitem>
          <listitem id="ch0065s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Jackson DW, Rohani P.</emphasis> 2014. Perplexities of pertussis: recent global epidemiological trends and their potential causes. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">142:</emphasis>672–684.</para>
          </listitem>
          <listitem id="ch0065s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Damron FH, Barbier M, Dubey P, Edwards KM, Gu XX, Klein NP, Lu K, Mills KHG, Pasetti MF, Read RC, Rohani P, Sebo P, Harvill ET.</emphasis> 2020. Overcoming Waning Immunity in Pertussis Vaccines: workshop of the National Institute of Allergy and Infectious Diseases. <citetitle><emphasis>J Immunol</emphasis></citetitle> <emphasis role="strong">205:</emphasis>877–882.</para>
          </listitem>
          <listitem id="ch0065s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Carrasquilla G, Porras A, Martinez S, DeAntonio R, Devadiga R, Caceres DC, Juliao P.</emphasis> 2020. Incidence and mortality of pertussis disease in infants &lt;12 months of age following introduction of pertussis maternal universal mass vaccination in Bogotá, Colombia. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">38:</emphasis>7384–7392.</para>
          </listitem>
          <listitem id="ch0065s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Ruiz-Botia I, Riera-Bosch MT, Rodriguez-Losada O, Soler-Palacin P, Melendo S, Moraga-Llop F, Balcells-Ramirez J, Otero-Romero S, Armadans-Gil L.</emphasis> 2022. Impact of vaccinating pregnant women against pertussis on hospitalizations of children under one year of age in a tertiary hospital in Catalonia. <citetitle><emphasis>Enferm Infecc Microbiol Clin (Engl Ed)</emphasis></citetitle> 10.1016/j.eimce.2022.06.002. Epub ahead of print.</para>
          </listitem>
          <listitem id="ch0065s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Zumstein J, Heininger U, Swiss Paediatric Surveillance Unit (SPSU).</emphasis> 2021. Decline of pertussis in hospitalised children following the introduction of immunisation in pregnancy—results from a nationwide, prospective surveillance study, 2013-2020. <citetitle><emphasis>Swiss Med Wkly</emphasis></citetitle> <emphasis role="strong">151:</emphasis>w30064.</para>
          </listitem>
          <listitem id="ch0065s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Njamkepo E, Bonacorsi S, Debruyne M, Gibaud SA, Guillot S, Guiso N.</emphasis> 2011. Significant finding of <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> DNA in nasopharyngeal samples from French patients with suspected pertussis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>4347–4348.</para>
          </listitem>
          <listitem id="ch0065s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Rodgers L, Martin SW, Cohn A, Budd J, Marcon M, Terranella A, Mandal S, Salamon D, Leber A, Tondella ML, Tatti K, Spicer K, Emanuel A, Koch E, McGlone L, Pawloski L, Lemaile-Williams M, Tucker N, Iyer R, Clark TA, Diorio M.</emphasis> 2013. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> and <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle>—Ohio, 2010-2011. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>322–331.</para>
          </listitem>
          <listitem id="ch0065s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Kanellopoulou M, Pournaras S, Iglezos H, Skarmoutsou N, Papafrangas E, Maniatis AN.</emphasis> 2004. Persistent colonization of nine cystic fibrosis patients with an <citetitle><emphasis>Achromobacter</emphasis></citetitle> (<citetitle><emphasis>Alcaligenes</emphasis></citetitle>) <citetitle><emphasis>xylosoxidans</emphasis></citetitle> clone. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>336–339.</para>
          </listitem>
          <listitem id="ch0065s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Krzewinski JW, Nguyen CD, Foster JM, Burns JL.</emphasis> 2001. Use of random amplified polymorphic DNA PCR to examine epidemiology of <citetitle><emphasis>Stenotrophomonas maltophilia</emphasis></citetitle> and <citetitle><emphasis>Achromobacter</emphasis></citetitle> (<citetitle><emphasis>Alcaligenes</emphasis></citetitle>) <citetitle><emphasis>xylosoxidans</emphasis></citetitle> from patients with cystic fibrosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>3597–3602.</para>
          </listitem>
          <listitem id="ch0065s000000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Cools P, Ho E, Vranckx K, Schelstraete P, Wurth B, Franckx H, Ieven G, Van Simaey L, Van Daele S, Verhulst S, De Baets F, Vaneechoutte M.</emphasis> 2016. Epidemic <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> strain among Belgian cystic fibrosis patients and review of literature. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>122.</para>
          </listitem>
          <listitem id="ch0065s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Gabrielaite M, Bartell JA, Nørskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, Marvig RL.</emphasis> 2021. Transmission and antibiotic resistance of <citetitle><emphasis>Achromobacter</emphasis></citetitle> in cystic fibrosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02911-20.</para>
          </listitem>
          <listitem id="ch0065s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Raso T, Bianco O, Grosso B, Zucca M, Savoia D.</emphasis> 2008. <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> respiratory tract infections in cystic fibrosis patients. <citetitle><emphasis>APMIS</emphasis></citetitle> <emphasis role="strong">116:</emphasis>837–841.</para>
          </listitem>
          <listitem id="ch0065s000000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, Van Simaey L, de Ganck C, De Baets F, Vaneechoutte M.</emphasis> 2005. Shared genotypes of <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> strains isolated from patients at a cystic fibrosis rehabilitation center. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2998–3002.</para>
          </listitem>
          <listitem id="ch0065s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Amoureux L, Bador J, Bounoua Zouak F, Chapuis A, de Curraize C, Neuwirth C.</emphasis> 2016. Distribution of the species of <citetitle><emphasis>Achromobacter</emphasis></citetitle> in a French cystic fibrosis centre and multilocus sequence typing analysis reveal the predominance of <citetitle><emphasis>A. xylosoxidans</emphasis></citetitle> and clonal relationships between some clinical and environmental isolates. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">15:</emphasis>486–494.</para>
          </listitem>
          <listitem id="ch0065s000000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N.</emphasis> 2011. Marked increase in incidence of <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> infections caused by sporadic acquisition from the environment. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">10:</emphasis>466–469.</para>
          </listitem>
          <listitem id="ch0065s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Hansen CR, Pressler T, Ridderberg W, Johansen HK, Skov M.</emphasis> 2013. <citetitle><emphasis>Achromobacter</emphasis></citetitle> species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">12:</emphasis>609–615.</para>
          </listitem>
          <listitem id="ch0065s000000li0065" role="bibliographyEntry">
            <anchor id="ch0065s000000a0065"/>
            <para>65.<emphasis role="strong">Patriarca PABR, Biellik RJ, Sanden G, Burstyn DG, Mitchell PD, Silverman PR, Davis JP, Manclark CR.</emphasis> 1988. Sensitivity and specificity of clinical case definitions for pertussis. <citetitle><emphasis>Am J Public Health</emphasis></citetitle> <emphasis role="strong">78:</emphasis>833–836.</para>
          </listitem>
          <listitem id="ch0065s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Haberling DL, Holman RC, Paddock CD, Murphy TV.</emphasis> 2009. Infant and maternal risk factors for pertussis-related infant mortality in the United States, 1999 to 2004. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">28:</emphasis>194–198.</para>
          </listitem>
          <listitem id="ch0065s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Moore A, Harnden A, Grant CC, Patel S, Irwin RS, Panel CEC, CHEST Expert Cough Panel.</emphasis> 2019. Clinically diagnosing pertussis-associated cough in adults and children: CHEST guideline and expert panel report. <citetitle><emphasis>Chest</emphasis></citetitle> <emphasis role="strong">155:</emphasis>147–154.</para>
          </listitem>
          <listitem id="ch0065s000000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, Tatti KM, Wu KH, Goldsmith CS, Greer PW, Montague JL, Eliason MT, Holman RC, Guarner J, Shieh WJ, Zaki SR.</emphasis> 2008. Pathology and pathogenesis of fatal <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> infection in infants. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">47:</emphasis>328–338.</para>
          </listitem>
          <listitem id="ch0065s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Cosnes-Lambe C, Raymond J, Chalumeau M, Pons-Catalano C, Moulin F, de Suremain N, Reglier-Poupet H, Lebon P, Poyart C, Gendrel D.</emphasis> 2008. Pertussis and respiratory syncytial virus infections. <citetitle><emphasis>Eur J Pediatr</emphasis></citetitle> <emphasis role="strong">167:</emphasis>1017–1019.</para>
          </listitem>
          <listitem id="ch0065s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Nadji S, Chopin MC, Bourdon C, Desbarbieux R, Marissael JM, Armand S, Wallet F, Loiez C.</emphasis> 2018. Spondylodiscitis caused by <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle>, a misrecognized pathogen emerging in invasive infections. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>95–97.</para>
          </listitem>
          <listitem id="ch0065s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Mir-Cros A, Codina G, Martín-Gómez MT, Fàbrega A, Martínez X, Jané M, Van Esso D, Cornejo T, Rodrigo C, Campins M, Pumarola T, González-López JJ.</emphasis> 2017. Emergence of <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> as a causative agent of whooping cough, Barcelona, Spain. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">23:</emphasis>1856–1859.</para>
          </listitem>
          <listitem id="ch0065s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Kukla R, Svarc M, Bolehovska R, Ryskova L, Paterova P, Fajfr M, Malisova L, Zemlickova H.</emphasis> 2020. Isolation of <citetitle><emphasis>Bordetella trematum</emphasis></citetitle> from the respiratory tract of a patient with lung cancer: a case report. <citetitle><emphasis>Folia Microbiol (Praha)</emphasis></citetitle> <emphasis role="strong">65</emphasis><emphasis role="strong">:</emphasis>623–627.</para>
          </listitem>
          <listitem id="ch0065s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Kitagawa D, Kurimoto T, Oyama S, Suzuki S, Masuo K, Suzuki Y, Nakano R, Sato M, Yano H, Maeda K, Nomi K, Nakamura F.</emphasis> 2021. A case of <citetitle><emphasis>Bordetella trematum</emphasis></citetitle> and <citetitle><emphasis>Kerstersia gyiorum</emphasis></citetitle> infections in a patient with congestive dermatitis. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">27:</emphasis>740–746.</para>
          </listitem>
          <listitem id="ch0065s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M.</emphasis> 2009. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">28:</emphasis>191–195.</para>
          </listitem>
          <listitem id="ch0065s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Gómez-Cerezo J, Suárez I, Ríos JJ, Peña P, García de Miguel MJ, de José M, Monteagudo O, Linares P, Barbado-Cano A, Vázquez JJ.</emphasis> 2003. <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> bacteremia: a 10-year analysis of 54 cases. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>360–363.</para>
          </listitem>
          <listitem id="ch0065s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Molina-Cabrillana J, Santana-Reyes C, González-García A, Bordes-Benítez A, Horcajada I.</emphasis> 2007. Outbreak of <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> pseudobacteremia in a neonatal care unit related to contaminated chlorhexidine solution. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">26:</emphasis>435–437.</para>
          </listitem>
          <listitem id="ch0065s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Kiredjian MHB, Kersters K, Guilvout I, De Ley J.</emphasis> 1986. <citetitle><emphasis>Alcaligenes piechaudii</emphasis></citetitle> sp. nov., a new species from human clinical specimens and the environment. <citetitle><emphasis>Int J Syst Bacteriol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>282–287.</para>
          </listitem>
          <listitem id="ch0065s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR.</emphasis> 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>158–163.</para>
          </listitem>
          <listitem id="ch0065s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M.</emphasis> 2007. <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> in cystic fibrosis: prevalence and clinical relevance. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">6:</emphasis>75–78.</para>
          </listitem>
          <listitem id="ch0065s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Degand N, Carbonnelle E, Dauphin B, Beretti JL, Le Bourgeois M, Sermet-Gaudelus I, Segonds C, Berche P, Nassif X, Ferroni A.</emphasis> 2008. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>3361–3367.</para>
          </listitem>
          <listitem id="ch0065s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Barrado L, Brañas P, Orellana MA, Martínez MT, García G, Otero JR, Chaves F.</emphasis> 2013. Molecular characterization of <citetitle><emphasis>Achromobacter</emphasis></citetitle> isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1927–1930.</para>
          </listitem>
          <listitem id="ch0065s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Spilker T, Liwienski AA, LiPuma JJ.</emphasis> 2008. Identification of <citetitle><emphasis>Bordetella</emphasis></citetitle> spp. in respiratory specimens from individuals with cystic fibrosis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">14:</emphasis>504–506.</para>
          </listitem>
          <listitem id="ch0065s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin HR, Surette MG, Parkins MD.</emphasis> 2017. Prevalence and outcomes of <citetitle><emphasis>Achromobacter</emphasis></citetitle> species infections in adults with cystic fibrosis: a North American cohort study. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>2074–2085.</para>
          </listitem>
          <listitem id="ch0065s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Hansen CRPT, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N.</emphasis> 2010. Inflammation in <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> infected cystic fibrosis patients. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">9:</emphasis>51–58.</para>
          </listitem>
          <listitem id="ch0065s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Gade SS, Nørskov-Lauritsen N, Ridderberg W.</emphasis> 2017. Prevalence and species distribution of <citetitle><emphasis>Achromobacter</emphasis></citetitle> sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">66:</emphasis>686–689.</para>
          </listitem>
          <listitem id="ch0065s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Coward A, Kenna DT, Perry C, Martin K, Doumith M, Turton JF.</emphasis> 2016. Use of nrdA gene sequence clustering to estimate the prevalence of different <citetitle><emphasis>Achromobacter</emphasis></citetitle> species among cystic fibrosis patients in the UK. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">15:</emphasis>479–485.</para>
          </listitem>
          <listitem id="ch0065s000000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">Rønne Hansen C, Pressler T, Høiby N, Gormsen M.</emphasis> 2006. Chronic infection with <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> in cystic fibrosis patients; a retrospective case control study. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">5:</emphasis>245–251.</para>
          </listitem>
          <listitem id="ch0065s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Wellinghausen N, Wirths B, Poppert S.</emphasis> 2006. Fluorescence <citetitle><emphasis>in situ</emphasis></citetitle> hybridization for rapid identification of <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> and <citetitle><emphasis>Alcaligenes faecalis</emphasis></citetitle> recovered from cystic fibrosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3415–3417.</para>
          </listitem>
          <listitem id="ch0065s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Vandamme P, De Brandt E, Houf K, De Baere T.</emphasis> 2012. <citetitle><emphasis>Kerstersia similis</emphasis></citetitle> sp. nov., isolated from human clinical samples. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">62:</emphasis>2156–2159.</para>
          </listitem>
          <listitem id="ch0065s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Wadowsky RM, Laus S, Libert T, States SJ, Ehrlich GD.</emphasis> 1994. Inhibition of PCR-based assay for <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> by using calcium alginate fiber and aluminum shaft components of a nasopharyngeal swab. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1054–1057.</para>
          </listitem>
          <listitem id="ch0065s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Riffelmann M, Wirsing von König CH, Caro V, Guiso N, Pertussis PCR Consesus Group.</emphasis> 2005. Nucleic acid amplification tests for diagnosis of <citetitle><emphasis>Bordetella</emphasis></citetitle> infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4925–4929.</para>
          </listitem>
          <listitem id="ch0065s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Fry NK, Duncan J, Wagner K, Tzivra O, Doshi N, Litt DJ, Crowcroft N, Miller E, George RC, Harrison TG.</emphasis> 2009. Role of PCR in the diagnosis of pertussis infection in infants: 5 years’ experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>1023–1029.</para>
          </listitem>
          <listitem id="ch0065s000000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Loeffelholz M.</emphasis> 2012. Towards improved accuracy of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> nucleic acid amplification tests. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2186–2190.</para>
          </listitem>
          <listitem id="ch0065s000000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Muyldermans G, Soetens O, Antoine M, Bruisten S, Vincart B, Doucet-Populaire F, Fry NK, Olcén P, Scheftel JM, Senterre JM, van der Zee A, Riffelmann M, Piérard D, Lauwers S.</emphasis> 2005. External quality assessment for molecular detection of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> in European laboratories. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>30–35.</para>
          </listitem>
          <listitem id="ch0065s000000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Templeton KE, Scheltinga SA, van der Zee A, Diederen BM, van Kruijssen A, Goossens H, Kuijper E, Claas EC.</emphasis> 2003. Evaluation of real-time PCR for detection of and discrimination between <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle>, <citetitle><emphasis>Bordetella parapertussis</emphasis></citetitle>, and <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> for clinical diagnosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4121–4126.</para>
          </listitem>
          <listitem id="ch0065s000000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Waters V, Jamieson F, Richardson SE, Finkelstein M, Wormsbecker A, Halperin SA.</emphasis> 2009. Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">28:</emphasis>582–587.</para>
          </listitem>
          <listitem id="ch0065s000000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Tizolova A, Guiso N, Guillot S.</emphasis> 2013. Insertion sequences shared by <citetitle><emphasis>Bordetella</emphasis></citetitle> species and implications for the biological diagnosis of pertussis syndrome. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>89–96.</para>
          </listitem>
          <listitem id="ch0065s000000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Roorda L, Buitenwerf J, Ossewaarde JM, van der Zee A.</emphasis> 2011. A real-time PCR assay with improved specificity for detection and discrimination of all clinically relevant <citetitle><emphasis>Bordetella</emphasis></citetitle> species by the presence and distribution of three insertion sequence elements. <citetitle><emphasis>BMC Res Notes</emphasis></citetitle> <emphasis role="strong">4:</emphasis>11.</para>
          </listitem>
          <listitem id="ch0065s000000li0099" role="bibliographyEntry">
            <anchor id="ch0065s000000a0066"/>
            <para>99.<emphasis role="strong">Tatti KM, Sparks KN, Boney KO, Tondella ML.</emphasis> 2011. Novel multitarget real-time PCR assay for rapid detection of <citetitle><emphasis>Bordetella</emphasis></citetitle> species in clinical specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>4059–4066.</para>
          </listitem>
          <listitem id="ch0065s000000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Register KB, Nicholson TL.</emphasis> 2007. Misidentification of <citetitle><emphasis>Bordetella bronchiseptica</emphasis></citetitle> as <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> using a newly described real-time PCR targeting the pertactin gene. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1608–1610.</para>
          </listitem>
          <listitem id="ch0065s000000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Reischl U, Lehn N, Sanden GN, Loeffelholz MJ.</emphasis> 2001. Real-time PCR assay targeting IS481 of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> and molecular basis for detecting <citetitle><emphasis>Bordetella holmesii. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1963–1966.</para>
          </listitem>
          <listitem id="ch0065s000000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Dalby T, Fry NK, Krogfelt KA, Jensen JS, He Q, pertussis EQA participants.</emphasis> 2013. Evaluation of PCR methods for the diagnosis of pertussis by the European surveillance network for vaccine-preventable diseases (<ulink url="http://EUVAC.NET">EUVAC.NET</ulink>). <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>1285–1289.</para>
          </listitem>
          <listitem id="ch0065s000000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Mandal S, Tatti KM, Woods-Stout D, Cassiday PK, Faulkner AE, Griffith MM, Jackson ML, Pawloski LC, Wagner B, Barnes M, Cohn AC, Gershman KA, Messonnier NE, Clark TA, Tondella ML, Martin SW.</emphasis> 2012. Pertussis pseudo-outbreak linked to specimens contaminated by <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> DNA from clinic surfaces. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">129:</emphasis>e424–e430.</para>
          </listitem>
          <listitem id="ch0065s000000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Wirsing von König CH, Riffelman M, Coenye T.</emphasis> 2011. <citetitle><emphasis>Bordetella</emphasis></citetitle> and related genera, p 739–750. <citetitle><emphasis>In</emphasis></citetitle> Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), <citetitle><emphasis>Manual of Clinical Microbiology</emphasis></citetitle>, 10th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0065s000000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Henry DA, Campbell ME, LiPuma JJ, Speert DP.</emphasis> 1997. Identification of <citetitle><emphasis>Burkholderia cepacia</emphasis></citetitle> isolates from patients with cystic fibrosis and use of a simple new selective medium. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>614–619.</para>
          </listitem>
          <listitem id="ch0065s000000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Wright RM, Moore JE, Shaw A, Dunbar K, Dodd M, Webb K, Redmond AOB, Crowe M, Murphy PG, Peacock S, Elborn JS.</emphasis> 2001. Improved cultural detection of <citetitle><emphasis>Burkholderia cepacia</emphasis></citetitle> from sputum in patients with cystic fibrosis. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>803–805.</para>
          </listitem>
          <listitem id="ch0065s000000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Moissenet D, Bingen E, Arlet G, Vu-Thien H.</emphasis> 2005. [Use of 16S rRNA gene sequencing for identification of “Pseudomonas-like” isolates from sputum of patients with cystic fibrosis]. <citetitle><emphasis>Pathol Biol (Paris)</emphasis></citetitle> <emphasis role="strong">53:</emphasis>500–502.</para>
          </listitem>
          <listitem id="ch0065s000000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Zintgraff J, Irazu L, Lara CS, Rodriguez M, Santos M.</emphasis> 2018. The classical <citetitle><emphasis>Bordetella</emphasis></citetitle> species and MALDI-TOF technology: a brief experience. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1737–1742.</para>
          </listitem>
          <listitem id="ch0065s000000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Weiss AA, Falkow S.</emphasis> 1984. Genetic analysis of phase change in <citetitle><emphasis>Bordetella pertussis. Infect Immun</emphasis></citetitle> <emphasis role="strong">43:</emphasis>263–269.</para>
          </listitem>
          <listitem id="ch0065s000000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Snyder JW, Munier GK, Johnson CL.</emphasis> 2008. Direct comparison of the BD phoenix system with the MicroScan WalkAway system for identification and antimicrobial susceptibility testing of <citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> and nonfermentative gram-negative organisms. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>2327–2333.</para>
          </listitem>
          <listitem id="ch0065s000000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Register KB, Sacco RE, Nordholm GE.</emphasis> 2003. Comparison of ribotyping and restriction enzyme analysis for inter- and intraspecies discrimination of <citetitle><emphasis>Bordetella avium</emphasis></citetitle> and <citetitle><emphasis>Bordetella hinzii. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1512–1519.</para>
          </listitem>
          <listitem id="ch0065s000000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Bosshard PP, Zbinden R, Abels S, Böddinghaus B, Altwegg M, Böttger EC.</emphasis> 2006. 16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1359–1366.</para>
          </listitem>
          <listitem id="ch0065s000000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Fontana C, Favaro M, Pelliccioni M, Pistoia ES, Favalli C.</emphasis> 2005. Use of the MicroSeq 500 16S rRNA gene-based sequencing for identification of bacterial isolates that commercial automated systems failed to identify correctly. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>615–619.</para>
          </listitem>
          <listitem id="ch0065s000000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Panagopoulos MI, Saint Jean M, Brun D, Guiso N, Bekal S, Ovetchkine P, Tapiero B.</emphasis> 2010. <citetitle><emphasis>Bordetella holmesii</emphasis></citetitle> bacteremia in asplenic children: report of four cases initially misidentified as <citetitle><emphasis>Acinetobacter lwoffii. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>3762–3764.</para>
          </listitem>
          <listitem id="ch0065s000000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Liu L, Coenye T, Burns JL, Whitby PW, Stull TL, LiPuma JJ.</emphasis> 2002. Ribosomal DNA-directed PCR for identification of <citetitle><emphasis>Achromobacter</emphasis></citetitle> (<citetitle><emphasis>Alcaligenes</emphasis></citetitle>) <citetitle><emphasis>xylosoxidans</emphasis></citetitle> recovered from sputum samples from cystic fibrosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1210–1213.</para>
          </listitem>
          <listitem id="ch0065s000000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Jacquier H, Carbonnelle E, Corvec S, Illiaquer M, Le Monnier A, Bille E, Zahar JR, Beretti JL, Jauréguy F, Fihman V, Tankovic J, Cattoir V.</emphasis> 2011. Revisited distribution of nonfermenting Gram-negative bacilli clinical isolates. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>1579–1586.</para>
          </listitem>
          <listitem id="ch0065s000000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Fernández-Olmos A, García-Castillo M, Morosini MI, Lamas A, Máiz L, Cantón R.</emphasis> 2012. MALDI-TOF MS improves routine identification of non-fermenting Gram negative isolates from cystic fibrosis patients. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">11:</emphasis>59–62.</para>
          </listitem>
          <listitem id="ch0065s000000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Marko DC, Saffert RT, Cunningham SA, Hyman J, Walsh J, Arbefeville S, Howard W, Pruessner J, Safwat N, Cockerill FR, Bossler AD, Patel R, Richter SS.</emphasis> 2012. Evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of nonfermenting gram-negative bacilli isolated from cultures from cystic fibrosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2034–2039.</para>
          </listitem>
          <listitem id="ch0065s000000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Rodrigues ER, Ferreira AG, Leão RS, Leite CC, Carvalho-Assef AP, Albano RM, Marques EA.</emphasis> 2015. Characterization of <citetitle><emphasis>Achromobacter</emphasis></citetitle> species in cystic fibrosis patients: comparison of <citetitle><emphasis>bla</emphasis></citetitle><subscript>OXA-114</subscript> PCR amplification, multilocus sequence typing, and matrix-assisted laser desorption ionization–time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3894–3896.</para>
          </listitem>
          <listitem id="ch0065s000000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Desai AP, Stanley T, Atuan M, McKey J, Lipuma JJ, Rogers B, Jerris R.</emphasis> 2012. Use of matrix assisted laser desorption ionisation-time of flight mass spectrometry in a paediatric clinical laboratory for identification of bacteria commonly isolated from cystic fibrosis patients. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">65:</emphasis>835–838.</para>
          </listitem>
          <listitem id="ch0065s000000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Garrigos T, Neuwirth C, Chapuis A, Bador J, Amoureux L.</emphasis> 2021. Development of a database for the rapid and accurate routine identification of Achromobacter species by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">27:</emphasis>126.e1–126.e5.</para>
          </listitem>
          <listitem id="ch0065s000000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Garrigos T, Dollat M, Magallon A, Chapuis A, Varin V, Bador J, Makki N, Cremet L, Persyn E, Cardot-Martin E, Echahidi F, Peeters C, Pierard D, Vandamme P, Verroken A, Neuwirth C, Amoureux L.</emphasis> 2021. Matrix-assisted laser desorption ionization–time of flight mass spectrometry for rapid detection of isolates belonging to the epidemic clones <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> ST137 and <citetitle><emphasis>Achromobacter ruhlandii</emphasis></citetitle> DES from cystic fibrosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e00946-21.</para>
          </listitem>
          <listitem id="ch0065s000000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Spilker T, Vandamme P, LiPuma JJ.</emphasis> 2013. Identification and distribution of <citetitle><emphasis>Achromobacter</emphasis></citetitle> species in cystic fibrosis. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">12:</emphasis>298–301.</para>
          </listitem>
          <listitem id="ch0065s000000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM.</emphasis> 2012. Population diversity among <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> isolates, United States, 1935-2009. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1248–1255.</para>
          </listitem>
          <listitem id="ch0065s000000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von König CH, Riffelmann M, Vahrenholz C, Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR.</emphasis> 2005. Analysis of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> populations in European countries with different vaccination policies. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2837–2843.</para>
          </listitem>
          <listitem id="ch0065s000000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, von Könnig CH, Riffelmann M, Mooi FR, Sandven P, Lutynska A, Fry NK, Mertsola J, He Q.</emphasis> 2013. Pulsed-field gel electrophoresis analysis of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> isolates circulating in Europe from 1998 to 2009. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>422–428.</para>
          </listitem>
          <listitem id="ch0065s000000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Litt DJ, Jauneikaite E, Tchipeva D, Harrison TG, Fry NK.</emphasis> 2012. Direct molecular typing of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> from clinical specimens submitted for diagnostic quantitative (real-time) PCR. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1662–1668.</para>
          </listitem>
          <listitem id="ch0065s000000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, Mertsola J, Advani A, Hallander HO, Janssens K, Hermans PW, Mooi FR.</emphasis> 2011. SNP-based typing: a useful tool to study <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> populations. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e20340.</para>
          </listitem>
          <listitem id="ch0065s000000li0129" role="bibliographyEntry">
            <anchor id="ch0065s000000a0067"/>
            <para>129.<emphasis role="strong">Kallonen T, Mertsola J, Mooi FR, He Q.</emphasis> 2012. Rapid detection of the recently emerged <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> strains with the ptxP3 pertussis toxin promoter allele by real-time PCR. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>E377–E379.</para>
          </listitem>
          <listitem id="ch0065s000000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Weigand MR, Peng Y, Pouseele H, Kania D, Bowden KE, Williams MM, Tondella ML.</emphasis> 2021. Genomic surveillance and improved molecular typing of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> using wgMLST. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e02726-20.</para>
          </listitem>
          <listitem id="ch0065s000000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Moissenet D, Baculard A, Valcin M, Marchand V, Tournier G, Garbarg-Chenon A, Vu-Thien H.</emphasis> 1997. Colonization by <citetitle><emphasis>Alcaligenes xylosoxidans</emphasis></citetitle> in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>274–275.</para>
          </listitem>
          <listitem id="ch0065s000000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Ridderberg W, Wang M, Nørskov-Lauritsen N.</emphasis> 2012. Multilocus sequence analysis of isolates of <citetitle><emphasis>Achromobacter</emphasis></citetitle> from patients with cystic fibrosis reveals infecting species other than <citetitle><emphasis>Achromobacter xylosoxidans. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2688–2694.</para>
          </listitem>
          <listitem id="ch0065s000000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford S III, Theel ES, Thomson RB Jr, Weinstein MP, Yao JD.</emphasis> 2018. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>813–816.</para>
          </listitem>
          <listitem id="ch0065s000000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, Elvers LH, Berbers GA, van Der Zee A, Schellekens JF.</emphasis> 2000. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with <citetitle><emphasis>Bordetella pertussis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>800–806.</para>
          </listitem>
          <listitem id="ch0065s000000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Guiso N, Berbers G, Fry NK, He Q, Riffelmann M, Wirsing von König CH, EU Pertstrain group.</emphasis> 2011. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>307–312.</para>
          </listitem>
          <listitem id="ch0065s000000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Kapasi A, Meade BD, Plikaytis B, Pawloski L, Martin MD, Yoder S, Rock MT, Coddens S, Haezebroeck V, Fievet-Groyne F, Bixler G, Jones C, Hildreth S, Edwards KM, Messonnier NE, Tondella ML.</emphasis> 2012. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">19:</emphasis>64–72.</para>
          </listitem>
          <listitem id="ch0065s000000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, Bernstein D, Edelman R, Edwards KM, Greenberg D, Keitel W, Treanor J, Ward JI, Study A, APERT Study.</emphasis> 2004. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">190:</emphasis>535–544.</para>
          </listitem>
          <listitem id="ch0065s000000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Baughman AL, Bisgard KM, Edwards KM, Guris D, Decker MD, Holland K, Meade BD, Lynn F.</emphasis> 2004. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">11:</emphasis>1045–1053.</para>
          </listitem>
          <listitem id="ch0065s000000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Yih WK, Lett SM, des Vignes FN</emphasis>, <emphasis role="strong">Garrison KM</emphasis>, <emphasis role="strong">Sipe PL</emphasis>, <emphasis role="strong">Marchant CD.</emphasis> 2000. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">182:</emphasis>1409–1416.</para>
          </listitem>
          <listitem id="ch0065s000000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Xing D, Wirsing von König CH, Newland P, Riffelmann M, Meade BD, Corbel M, Gaines-Das R.</emphasis> 2009. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>303–311.</para>
          </listitem>
          <listitem id="ch0065s000000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Versteegh FG, Mertens PL, de Melker HE, Roord JJ, Schellekens JF, Teunis PF.</emphasis> 2005. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with <citetitle><emphasis>Bordetella pertussis. Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">133:</emphasis>737–748.</para>
          </listitem>
          <listitem id="ch0065s000000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Mertens PL, Stals FS, Steyerberg EW, Richardus JH.</emphasis> 2007. Sensitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>53.</para>
          </listitem>
          <listitem id="ch0065s000000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Pebody RG, Gay NJ, Giammanco A, Baron S, Schellekens J, Tischer A, Olander RM, Andrews NJ, Edmunds WJ, Lecoeur H, Lévy-Bruhl D, Maple PA, de Melker H, Nardone A, Rota MC, Salmaso S, Conyn-van Spaendonck MA, Swidsinski S, Miller E.</emphasis> 2005. The seroepidemiology of <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> infection in Western Europe. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">133:</emphasis>159–171.</para>
          </listitem>
          <listitem id="ch0065s000000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Pawloski LC, Plikaytis BD, Martin MD, Martin SW, Prince HE, Lapé-Nixon M, Tondella ML.</emphasis> 2017. Evaluation of commercial assays for single-point diagnosis of pertussis in the US. <citetitle><emphasis>J Pediatric Infect Dis Soc</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e15–e21.</para>
          </listitem>
          <listitem id="ch0065s000000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Riffelmann M, Hunfeld KP, Müller I, Xing D, Kennerknecht N, Wirsing von König CH.</emphasis> 2013. External quality assessment of pertussis serology in Germany. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>421–423.</para>
          </listitem>
          <listitem id="ch0065s000000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Li L, Deng J, Ma X, Zhou K, Meng Q, Yuan L, Shi W, Wang Q, Li Y, Yao K.</emphasis> 2019. High prevalence of macrolide-resistant <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> and ptxP1 genotype, mainland China, 2014-2016. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">25:</emphasis>2205–2214.</para>
          </listitem>
          <listitem id="ch0065s000000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Zhang J, Zhang D, Wang X, Wei X, Li H.</emphasis> 2022. Macrolide susceptibility and molecular characteristics of <citetitle><emphasis>Bordetella pertussis. J Int Med Res</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3000605221078782.</para>
          </listitem>
          <listitem id="ch0065s000000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Zhang Q, Li M, Wang L, Xin T, He Q.</emphasis> 2013. High-resolution melting analysis for the detection of two erythromycin-resistant <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> strains carried by healthy schoolchildren in China. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">19:</emphasis>E260–E262.</para>
          </listitem>
          <listitem id="ch0065s000000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Feng Y, Chiu CH, Heininger U, Hozbor DF, Tan TQ, von König CW.</emphasis> 2021. Emerging macrolide resistance in <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> in mainland China: findings and warning from the global pertussis initiative. <citetitle><emphasis>Lancet Reg Health W Pac</emphasis></citetitle> <emphasis role="strong">8:</emphasis>100098.</para>
          </listitem>
          <listitem id="ch0065s000000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Yamaguchi T, Kawasaki Y, Katsukawa C, Kawahara R, Kawatsu K.</emphasis> 2020. The first report of macrolide-resistant <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle> isolation in Japan. <citetitle><emphasis>Jpn J Infect Dis</emphasis></citetitle> <emphasis role="strong">73</emphasis><emphasis role="strong">:</emphasis>361–362.</para>
          </listitem>
          <listitem id="ch0065s000000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Kamachi K, Duong HT, Dang AD, Hai T, Do D, Koide K, Otsuka N, Shibayama K, Hoang HTT.</emphasis> 2020. Macrolide-resistant <citetitle><emphasis>Bordetella pertussis</emphasis></citetitle>, Vietnam, 2016-2017. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">26:</emphasis>2511–2513.</para>
          </listitem>
          <listitem id="ch0065s000000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Altunaiji S, Kukuruzovic R, Curtis N, Massie J.</emphasis> 2007. Antibiotics for whooping cough (pertussis). <citetitle><emphasis>Cochrane Database Syst Rev</emphasis></citetitle> <emphasis role="strong">2007</emphasis>(3)<emphasis role="strong">:</emphasis>CD004404.</para>
          </listitem>
          <listitem id="ch0065s000000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Kadlec K, Wiegand I, Kehrenberg C, Schwarz S.</emphasis> 2007. Studies on the mechanisms of beta-lactam resistance in <citetitle><emphasis>Bordetella bronchiseptica. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>396–402.</para>
          </listitem>
          <listitem id="ch0065s000000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Mortensen JE, Brumbach A, Shryock TR.</emphasis> 1989. Antimicrobial susceptibility of <citetitle><emphasis>Bordetella avium</emphasis></citetitle> and <citetitle><emphasis>Bordetella bronchiseptica</emphasis></citetitle> isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">33:</emphasis>771–772.</para>
          </listitem>
          <listitem id="ch0065s000000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Schwarz S, Alesík E, Grobbel M, Lübke-Becker A, Werckenthin C, Wieler LH, Wallmann J.</emphasis> 2007. Antimicrobial susceptibility of <citetitle><emphasis>Pasteurella multocida</emphasis></citetitle> and <citetitle><emphasis>Bordetella bronchiseptica</emphasis></citetitle> from dogs and cats as determined in the BfT-GermVet monitoring program 2004-2006. <citetitle><emphasis>Berl Munch Tierarztl Wochenschr</emphasis></citetitle> <emphasis role="strong">120:</emphasis>423–430.</para>
          </listitem>
          <listitem id="ch0065s000000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Glupczynski Y, Hansen W, Freney J, Yourassowsky E.</emphasis> 1988. In vitro susceptibility of <citetitle><emphasis>Alcaligenes denitrificans</emphasis></citetitle> subsp. xylosoxidans to 24 antimicrobial agents. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">32:</emphasis>276–278.</para>
          </listitem>
          <listitem id="ch0065s000000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S.</emphasis> 2001. Identification and antimicrobial susceptibility of <citetitle><emphasis>Alcaligenes xylosoxidans</emphasis></citetitle> isolated from patients with cystic fibrosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>3942–3945.</para>
          </listitem>
          <listitem id="ch0065s000000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Saiman L, Chen Y, Gabriel PS, Knirsch C.</emphasis> 2002. Synergistic activities of macrolide antibiotics against <citetitle><emphasis>Pseudomonas aeruginosa</emphasis></citetitle>, <citetitle><emphasis>Burkholderia cepacia</emphasis></citetitle>, <citetitle><emphasis>Stenotrophomonas maltophilia</emphasis></citetitle>, and <citetitle><emphasis>Alcaligenes xylosoxidans</emphasis></citetitle> isolated from patients with cystic fibrosis. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1105–1107.</para>
          </listitem>
          <listitem id="ch0065s000000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Pereira RH, Leão RS, Carvalho-Assef AP, Albano RM, Rodrigues ER, Firmida MC, Folescu TW, Plotkowski MC, Bernardo VG, Marques EA.</emphasis> 2017. Patterns of virulence factor expression and antimicrobial resistance in <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> and <citetitle><emphasis>Achromobacter ruhlandii</emphasis></citetitle> isolates from patients with cystic fibrosis. <citetitle><emphasis>Epidemiol Infect</emphasis></citetitle> <emphasis role="strong">145:</emphasis>600–606.</para>
          </listitem>
          <listitem id="ch0065s000000li0160" role="bibliographyEntry">
            <anchor id="ch0065s000000a0068"/>
            <para>160.<emphasis role="strong">Okoliegbe IN, Hijazi K, Cooper K, Ironside C, Gould IM.</emphasis> 2020. Longitudinal surveillance and combination antimicrobial susceptibility testing of multidrug-resistant <citetitle><emphasis>Achromobacter</emphasis></citetitle> species from cystic fibrosis patients. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>e01467-20.</para>
          </listitem>
          <listitem id="ch0065s000000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Chalhoub H, Kampmeier S, Kahl BC, Van Bambeke F.</emphasis> 2022. Role of efflux in antibiotic resistance of <citetitle><emphasis>Achromobacter xylosoxidans</emphasis></citetitle> and <citetitle><emphasis>Achromobacter insuavis</emphasis></citetitle> isolates from patients with cystic fibrosis. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>762307.</para>
          </listitem>
          <listitem id="ch0065s000000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Kay SE, Clark RA, White KL, Peel MM.</emphasis> 2001. Recurrent <citetitle><emphasis>Achromobacter piechaudii</emphasis></citetitle> bacteremia in a patient with hematological malignancy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>808–810.</para>
          </listitem>
          <listitem id="ch0065s000000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV, Skov M, Lemming LE, Pressler T, Johansen HK, Nørskov-Lauritsen N.</emphasis> 2013. Early treatment with inhaled antibiotics postpones next occurrence of <citetitle><emphasis>Achromobacter</emphasis></citetitle> in cystic fibrosis. <citetitle><emphasis>J Cyst Fibros</emphasis></citetitle> <emphasis role="strong">12:</emphasis>638–643.</para>
          </listitem>
          <listitem id="ch0065s000000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Nielsen SM, Nørskov-Lauritsen N, Bjarnsholt T, Meyer RL.</emphasis> 2016. <citetitle><emphasis>Achromobacter</emphasis></citetitle> species isolated from cystic fibrosis patients reveal distinctly different biofilm morphotypes. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">4:</emphasis>33.</para>
          </listitem>
          <listitem id="ch0065s000000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Tom SK, Yau YC, Beaudoin T, LiPuma JJ, Waters V.</emphasis> 2015. Effect of high-dose antimicrobials on biofilm growth of <citetitle><emphasis>Achromobacter</emphasis></citetitle> species isolated from cystic fibrosis patients. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>650–652.</para>
          </listitem>
          <listitem id="ch0065s000000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Bizet C, Tekaia F, Philippon A.</emphasis> 1993. In-vitro susceptibility of <citetitle><emphasis>Alcaligenes faecalis</emphasis></citetitle> compared with those of other <citetitle><emphasis>Alcaligenes</emphasis></citetitle> spp. to antimicrobial agents including seven beta-lactams. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">32:</emphasis>907–910.</para>
          </listitem>
          <listitem id="ch0065s000000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Pence MA, Sharon J, McElvania Tekippe E, Pakalniskis BL, Ford BA, Burnham CA.</emphasis> 2013. Two cases of <citetitle><emphasis>Kerstersia gyiorum</emphasis></citetitle> isolated from sites of chronic infection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2001–2004.</para>
          </listitem>
          <listitem id="ch0065s000000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Almuzara MN, Barberis CM, Traglia GM, Ordoñez AM, Famiglietti AM, Ramirez MS, Vay CA.</emphasis> 2012. Isolation of <citetitle><emphasis>Kerstersia gyiorum</emphasis></citetitle> from a patient with cholesteatomatous chronic otitis media. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3809–3811.</para>
          </listitem>
          <listitem id="ch0065s000000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Tatti KM, Martin SW, Boney KO, Brown K, Clark TA, Tondella ML.</emphasis> 2013. Qualitative assessment of pertussis diagnostics in United States laboratories. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">32:</emphasis>942–945.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
